

# Telehealth-supported exercise/physical activity programs for knee osteoarthritis: A systematic review and meta-analysis

### Chengqi HE ( Markfhcq2015@126.com )

West China Hospital, Sichuan University

### Xiao-Na Xiang

West China Hospital, Sichuan University https://orcid.org/0000-0001-8659-1080

### Ze-Zhang Wang

West China School of Medicine, Sichuan University

### Jiang-Yin Zhang

West China Hospital, Sichuan University

#### Ke Li

Southwestern University of Finance and Economics

### Qi-Xu Chen

Southwestern University of Finance and Economics

#### Fa-Shu Xu

West China Hospital, Sichuan University

### Yue-Wen Zhang

Southwestern University of Finance and Economics

#### Hong-Chen He

West China Hospital, Sichuan University

### Si-Yi Zhu

West China Hospital, Sichuan University

### Article

Keywords: Telehealth, Knee osteoarthritis, Physical activities, Quality of life, Systematic review and meta-analysis

Posted Date: March 20th, 2023

### DOI: https://doi.org/10.21203/rs.3.rs-2407444/v1

License: 🐵 🕐 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

### Abstract

The integration of telehealth-supported programs in chronic disease management has become more common, but it is unclear if this approach is effective for individuals with knee osteoarthritis. This study aimed to assess the effectiveness of telehealth-supported exercise/physical activity programs in individuals with knee osteoarthritis. A comprehensive literature search was conducted in September 2022 on randomized controlled trials compared telehealth-supported exercise/physical activity programs to a control condition for knee osteoarthritis. Twenty-three studies met eligibility criteria, of which 20 studies included in the meta-analysis. The results showed that telehealth-supported exercise/physical activity programs reduced pain (g = -0.39, Cl -0.67 to -0.11, l<sup>2</sup> = 83%), improved physical activity (g = 0.13, Cl 0.03 to 0.23, l<sup>2</sup> = 0%) and enhanced physical function (g = -0.51, Cl -0.98 to -0.05, l<sup>2</sup> = 87%). In addition, better improvements in quality of life, self-efficacy for pain, and global improvement were observed, but self-efficacy for physical function showed insignificant improvements. The results indicate that a telehealth-supported exercise/physical activity program could be an effective treatment for knee osteoarthritis. Future research should consider longer implementation durations and the feasibility of incorporating wearables and standardized components into large-scale interventions to evaluate the effects.

### 1. Introduction

Osteoarthritis is a degenerative joint disease affecting over 500 million individuals globally<sup>1</sup>, of whom more than 260 million have knee osteoarthritis (KOA) with notable health and socioeconomic costs<sup>2</sup>. The prevalence of KOA for the 60-year-old participants was 26.8%<sup>3</sup>, and a model forecasted that KOA will prevail in 2.37 billion individuals over 65 years and 866 million individuals over 80 years in 2100 globally<sup>4</sup>. The disease resulted in 9.6 million years of disability survivals (YLDs) worldwide, accounting for a 9.6% increase in the global percentage change of age-standardised YLDs between 1990-2017<sup>5,6</sup>. Risk factors of KOA (ie, aging, overweight, obesity) are capable of aggravating pain and disability, accelerating osteoarthritis progression, and lastly increasing the likelihood of costly joint replacement surgery<sup>7,8</sup>. It is estimated that the annual count of knee arthroplasty procedures will increase to 4 million by 2040 in the USA alone<sup>9</sup>.

As no disease-modifying drugs are available for KOA, non-pharmacologic interventions become the core treatment.<sup>10</sup> In the early stage, pain and stiffness dominate symptoms over others, therefore, the management strategy focuses on the reduction of pain and the improvement of functional capacities.<sup>11</sup> Clinical guidelines recommend strategies about maintaining active physical activity and exercise as first-line management for knee osteoarthritis<sup>2,12,13</sup>. However, gaps exist in the clinical use of active lifestyle strategies and exercise for KOA, with overusing medication and surgery<sup>14</sup>. Although the demand for effective intervention to cope with the need for decreased function related to an inactive lifestyle and aging seems urgent, in-person services provided by health professionals, especially physiotherapists, can be expensive regarding costs and time spent consulting an expert and the commute<sup>15</sup>. Besides the low time-efficiency and high cost, the lack of motivation is also a barrier since adherence to home-based exercise decreased by 94.7% after the 3 months from being discharged<sup>16</sup>.

Telehealth is defined as 'the delivery and facilitation of health and health-related services including medical care, provider and patient education, health information services, and self-care via telecommunications and digital communication technologies'<sup>17,18</sup>. An accumulating body of evidence suggests that telehealth-supported exercise intervention has been proven as a preferable form of intervention, especially due to the 'social distancing' requirement imposed by the COVID-19 pandemic. Hence, the need in seeking advice or interventions via telehealth has soared<sup>19,20</sup>. Nonetheless, as individuals with KOA tend to be older, digital communications may have disadvantages over traditional rehabilitation due to its unclear instructions, unfamiliarity, barriers related to devices such as using a smartphone or registering on an application, and availability of Wi-Fi or cellular data.

Several reviews have attempted to confirm the efficacy of telehealth-supported exercise programs in individuals with KOA, but merely focused on the efficacy of telehealth-supported physical activity programs. Our previous meta-analysis<sup>21</sup> (k = 4) indicated pain relief in patients with KOA following Internet-based rehabilitation, but the effect on physical function (g = -0.08, 95% CI: -0.27 to 0.12) was unclear due to the limited original studies included. As the intervention in the review was not inclusive (ie, programs delivered via wearables, telephone, and email were not included), the conclusion may not be robust to explain the effect of telehealth-supported exercise programs. Another meta-analysis<sup>22</sup> (k = 12) using interventions via computer and virtual reality reported no improvement in physical function either (g = 0.22, 95% CI: 0 to 0.43). The latest meta-analysis of 9 RCTs by Yang and colleagues<sup>23</sup> indicated the telehealth-based exercise intervention was better than usual care in improving pain and able to achieve similar effects of physical function compared to in-person exercise programs (g = -0.17, 95%-CI: -0.42 to 0.08). The results of physical function are negative mainly due to the different interventions and comparators in these reviews, especially components of telehealth-supported exercise programs vary among studies. In addition, the effects on physical activity and self-efficacy in coping with symptoms and global improvement experienced by patients are not investigated.

As numerous studies have researched the effect of telehealth-based exercise/physical activity programs in KOA<sup>24-33</sup>, we did a systematic review and metaanalysis to investigate the effect of telehealth-supported exercise/physical activity programs on pain, physical activity, physical function, self-efficacy, quality of life and global improvement. Furthermore, the minimal important differences (MIDs) are important considerations in making clinical conclusions and are reported in this study.

### 2. Results

### Study selection

A total of 14081 and an additional 13 articles were retrieved from databases. After removing duplicates, 4021 records were screened for the titles and abstracts. A total of 86 full-text articles were assessed for eligibility. Of these, 23 articles<sup>24-48</sup> were included in the systematic review (see Fig. 1). List of studies

excluded at the full-text screening stage with reasons is in Supplementary Table 1. Three articles<sup>35,47,48</sup> were excluded for the meta-analysis due to nonstandard data reporting, resulting in 20 articles being included in the meta-analysis.

### Characteristics of included studies

The characteristics of all included studies are described in Table 1. A total of 23 studies involved 3824 patients, of which 60% of the participants were female, were included in the systematic review. One study<sup>27</sup> observed the effect in the female population only, and others recruited participants of both sexes. Two (9%) studies were conducted in Europe, five (22%) in North America, five (22%) in Asia, nine (39%) in Australia, and two (9%) in Africa. The age of included participants was 61 (SD 3.9) years. The study period varied between 4 and 96 weeks, with seven trials (30%) performing the telehealth-based intervention for less than 3 months, six (26%) between three to six months, and 9 (39%) more than 6 months. 13 (57%) studies received telehealth-supported exercise programs, four (17%) received a physical activity program, and six (26%) received both treatments in combination. These studies tested different digital technologies, including mobile applications (k = 4), telephone (k = 4), Internet (k = 4), SMS (k = 2), and combinations (k = 9). Moreover, studies tested different additional components, such as reminder alone (k = 4), remote coaching alone (k = 3), remote monitoring alone (k = 3), combined remote reminder and monitoring (k = 2), combined remote coaching and monitoring (k = 7), with fewer studies focused on combined remote reminder and coaching (k = 1) and combined all (k = 1). For models of telehealth delivery, 8 (35%) studies used virtual contact, 5 (22%) studies used no interacting contact, 5 (22%) studies used mixed models, and one study (4%) used in-person delivery.

### **Risk of bias**

Risk of bias appraised with the Cochrane Collaboration's risk of bias tool and additional PEDro scale are presented in Supplementary Fig. 1 and Supplementary Table 2. Risk of bias assessment revealed the following sources of bias: the absence of adequate random sequence generation in five (22%) studies<sup>31,35,45,46,48</sup>; no details of allocation concealment in five (22%) studies<sup>29,32,35,46,47</sup>; participants and personnel were unblinded in all studies (100%)<sup>24-48</sup> limited by the intervention; the absence of the blinding of outcome assessment in nine studies (39%)<sup>25,27,31,35,38,41,46-48</sup>; insufficient strategies for dealing with incomplete outcome data in six (26%) studies<sup>24,27,28,32,46,47</sup>; no reporting bias in all studies and the presence of other bias in four studies (17%) (including insufficient power<sup>27</sup> and without clinical registration<sup>46-48</sup>).

### Main analyses

Of these studies, 20 (87%) studies contributed data that were considered appropriate for meta-analysis. The GRADE summary of findings can be found in Supplementary Table 3. Meta-analysis results of the effects of telehealth-based exercise/physical activity programs on primary outcomes are presented in Table 2.

### Effectiveness on pain

For pain relief, there was a significant difference and a small effect size across 19 studies (n = 2512; g = -0.39; 95% Cl -0.67 to -0.11; *p* = 0.0004; forest plot Fig. 2A) with high heterogeneity ( $l^2$ =83%) for favouring the telehealth-based intervention. The calculated MID of pain was 1.3, which was lower than the reported MID (2.0 units for the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale).<sup>49</sup> Overall, there was low-certainty evidence that the telehealth-based exercise/physical activity programs led to a small, significant, but not clinically meaningful reduction in pain.

### Effectiveness on physical activity

The meta-analysis result across nine studies for physical activity favoured the telehealth-based intervention (n = 1570; g = 0.13; 95% Cl 0.03 to 0.23; p = 0.01; forest plot Fig. 2B) with low heterogeneity ( $l^2$  = 0%). The calculated MID of physical activity was 9.0, which was lower than the reported MID (46.0 units for Physical Activity Scale for the Elderly).<sup>50</sup> Overall, there was low-certainty evidence that the telehealth-based exercise/physical activity programs for the treatment of KOA might provide a significant, but insufficient, and not clinically meaningful improvement in physical activity.

### Effectiveness on physical function

For the improvement of physical function, the meta-analysis of 18 RCTs favoured the telehealth-based intervention with g = -0.51 (n = 2373; 95% Cl -0.98 to -0.05; p = 0.0004;  $l^2 = 87\%$ ; forest plot Fig. 2C). The calculated MID of physical function was 5.3, which was lower than the reported MID (10.1 units for the WOMAC physical function subscale).<sup>51</sup> Overall, there was low-certainty evidence that telehealth-based exercise/physical activity programs might lead to a moderate, significant, but not clinically meaningful improvement in physical function.

### Effectiveness on secondary outcomes

Better secondary outcomes, such as quality of life (n = 1301; g = 0.25; 95% Cl 0.14 to 0.36; p <0.00001;  $l^2$  = 5%; Supplementary Fig. 2), self-efficacy for pain (n = 1337; g = 0.72; 95% Cl 0.53 to 0.91; p < 0.00001;  $l^2$  = 4%; Supplementary Fig. 2), and global improvement (n=1042; odds ratios [OR] = 2.69; 95% Cl 1.41 to 5.15; p=0.0005;  $l^2$  = 79%; Supplementary Fig. 2) were observed with the intervention groups compared with control groups, but with a non-significant trend and moderate heterogeneity between studies for self-efficacy for physical function (n = 578; g = 0.14; 95% Cl -0.26 to 0.53; p = 0.50;  $l^2$  = 52%; Supplementary Fig. 2). Overall, there was moderate-certainty evidence that telehealth-based exercise/physical activity programs improved the quality of life and self-efficacy for physical function might provide benefit in global improvement, but not significant in self-efficacy for physical function.

### Sensitivity analyses

After removing one study<sup>29</sup>, the overall significant effect size for pain relief was still small with g = -0.28 (n = 2448; 95% CI -0.44 to -0.11; *p*=0.0003; Supplementary Fig. 3) and a lower heterogeneity ( $l^2 = 69\%$ ), which was a robust result. Moreover, after omitting the study<sup>29</sup>, the overall significant effect size for physical function improvement was small with g = -0.30 (n = 2309; 95% CI -0.47 to -0.13; *p* = 0.0002; Supplementary Fig. 3) with a lower heterogeneity ( $l^2 = 69\%$ ).

### Subgroup analysis

The result of the meta-regression test is listed in Supplementary Table 4. According to the World Health Organization (WHO) classification, studies were divided into (1) interventions for clients subgroup, (2) interventions for healthcare providers subgroup, and (3) interventions for clients and healthcare providers subgroup. In subgroup that included interventions for clients and healthcare providers, the effects of the telehealth-based intervention on pain (g = -0.29; 95% Cl -0.49 to -0.09) and physical function (g = -0.36; 95% Cl -0.63 to -0.08) were significant. However, no significant differences were found in both pain (g = -0.73; 95% Cl -1.47 to 0.01) and physical function (g = -0.98; 95% Cl -2.21 to 0.26) in interventions for clients subgroup. The interventions for healthcare providers subgroup showed that participants in the intervention group had no improvement in pain relief (g = 0.21; 95% Cl -0.20 to 0.62) and physical function (g = 0.20; 95% Cl -0.21 to 0.61) compared with the control group, either. The subgroup differences were significant in pain (p = 0.039) and physical function (p = 0.04), although heterogeneity was still significant in some of these sub-groups ( $f^2$ >50%, Fig. 3).

As for the type of digital technologies in intervention group, the subgroup differences were significant in pain (p = 0.003) and physical function (p = 0.012) with high heterogeneity in mixed and SMS subgroup ( $l^2 > 50\%$ , Fig. 4). The subgroup analysis showed significant relief in pain (mobile application subgroup: g = -0.59 (95% CI -1.01 to -0.16); Internet subgroup: g = -0.25 (95% CI -0.43 to -0.07); and mixed type: g = -0.29 (95% CI -0.57 to -0.01)), and significant improvement in physical function (mobile application subgroup: g = -0.73 (95% CI -1.10 to -0.36); Internet subgroup: g = -0.42 (95% CI -0.80 to -0.04); and mixed type: g = -0.28 (95% CI -0.54 to -0.02)). Nonetheless, interventions with telephone and SMS subgroup showed both non-significant results in pain (g = -0.08; 95% CI -0.34 to 0.18) and g = -1.41; 95% CI -4.54 to 1.73), respectively) and physical function (g = 0.01; 95% CI -0.22 to 0.23) and g = -2.45; 95% CI -7.39 to 2.48, respectively).

The control treatments in included studies were divided into active controls (ie, exercise, physical therapy, and self-management) or inactive controls (ie, education, usual care, and waitlist) with subgroup differences (pain p = 0.021; physical function p = 0.065, Fig. 5). Compared with the active control groups, no statistically significant difference in pain (g = -0.08; 95% CI -0.21 to 0.05) and physical function (g = -0.07; 95% CI -0.21 to 0.07) was determined. Compared with inactive control groups, statistically significant pain reduction (g = -0.63; 95% CI -1.08 to -0.18) and function improvement (g = -0.79; 95% CI -1.54 to -0.03) were found in the intervention group.

### **Publication bias**

Visual assessment of funnel plots for studies reporting pain relief, and improvement in physical activity and function did not suggest publication bias (see Supplementary Fig. 4) and these were supported by Egger's regression test for plot (see Table 2).

### 3. Discussion

We systematically reviewed the effectiveness of telehealth-supported exercise/physical activity programs on pain, physical activity, physical function, selfefficacy, quality of life, and global improvement among individuals with KOA. Overall, this review found low-certainty evidence that telehealth-supported programs might show a small benefit on pain, a very small effect on physical activity, and a moderated effect on physical function, although these changes of primary outcomes were not significant in clinical difference. Additionally, this review found moderate-certainty evidence that telehealth-supported exercise/physical activity programs might provide a statistical improvement in quality of life and self-efficacy for pain, and low-certainty evidence that telehealth-supported interventions might increase global improvement. But we found low-certainty evidence suggesting that telehealth-supported exercise/physical activity programs made no significant improvement in self-efficacy for physical function. Of studies that were categorized as interventions for clients and healthcare providers according to WHO classification (v1.0)<sup>52</sup>, the benefits in pain relief and physical function improvement were found. We also found that digital technology affected the results, and positive effects were only delivered by mobile applications, Internet, and mixed type. Additionally, our subgroup analysis of control interventions indicated that telehealth-supported exercise/physical activity programs had a greater increase in pain and function than inactive intervention did. Although we thought the reminder, monitoring, and coaching should be important components of telehealth-supported programs, no significant subgroup difference was found. These findings suggest a definite role for telehealth-supported exercise/physical activity programs in the management of KOA, and formative research is required to better understand the trend in telehealth technology, and the component of telehealthsupported programs.

Although we reported the benefits of telehealth-supported exercise/physical activity programs, no improvements were determined in the self-efficacy for physical function represented the perceived capability to improve physical function, which is subjective and causally influences outcome expectancies, but not vice versa<sup>53</sup>. In our meta-analysis, more objective result by scales indicated that improvement in physical function might exist. Nonetheless, the inconsistency with the results of self-efficacy for physical function. This condition might reflect the influence of previous studies. Only two meta-analyses<sup>22,23</sup> reported the effects of telehealth-based exercise programs on physical function, and reported negative conclusions. These dispiriting results might decrease the motivation for physical function. Moreover, exercise is one type of planned, structured, and repetitive physical activity<sup>54</sup>, it is more essential to determine the effect of telehealth-based physical activity programs. Most telehealth-based programs contained strategies about improving activities of sports, daily living, occupation, leisure, active transportation, and energy expenditure above resting levels, that aimed at improving physical

activity. Therefore, our meta-analysis included studies involving telehealth-based exercise or physical activity interventions and changed the conclusion about physical function.

Multiple factors affected the performance of telehealth-based interventions and resulted in high heterogeneity. We did sensitive and subgroup analysis to explain the source of heterogeneity, and we found the study of Rafiq and the colleagues increased the heterogeneity because their results of telehealth-based programs reflected huge improvements. The improvements might be caused by telehealth-based strengthening exercise programs and the reminders to clients that required clients to complete the exercise session<sup>29</sup>. Reminders may increase the effect of telehealth programs by improving adherence to telemedicine potentially<sup>55</sup>. Nonetheless, our review did not identify evidence of heterogeneity and effect when comparing whether the telehealth-based programs with a reminder, coaching, and monitoring or not. Consultations or coaching, as a professional continuous service, might play an important role in transmitting health information and providing decision support<sup>56</sup>. Palamara and colleagues<sup>57</sup> reported an improvement in well-being among female surgery residents who received vital coaching over a web-based video platform. Nonetheless, Sieczkowska et al.<sup>58</sup> revealed the available evidence is not of sufficient quality to support the use of self-reported health coaching as a health care intervention for weight loss. Although face-to-face clinician contact might be considered crucial for the delivery of available specialist knowledge, consultations or coaching between remote client and healthcare provider<sup>59</sup>, targeted alerts and reminders to clients<sup>60</sup>, and remote monitoring of client<sup>61</sup> could still be controversial. More studies with strict design should focus on the effect of remote consultations, coaching, reminders, and monitoring to standardise the format components of telehealth-based exercise/physical activity programs and understand the clinical importance of telehealth-supported exercise/physical activity programs.

Besides the components in programs, we found the targeted primary users, digital technology, and comparators were more important in our study. We have classified the telehealth-based programs with the WHO classification (v1.0)<sup>52</sup>, which is a good and useful tool for identifying the characteristics of telemedicine. Our results emphasized the interactions between clients and health providers contributed to improvement of pain and physical function. This WHO classification of digital health interventions matched the trend of digital technologies, and might will be developed to constrain smart technologies, such as robotics-assisted training, physical therapy device, and exercise sensors via the Internet of things<sup>62</sup>. As for technology delivered the telehealth-based programs, only two studies<sup>25,43</sup> used wearables for personal data tracking, which was consistent with the conclusion that nonoperative osteoarthritis patients were generally unreceptive to using wearable technologies<sup>63</sup>. Most recent trials employed mobile applications and the Internet, that reflect personal telemedicine devices might be the trend of delivery methods, recent societal and technological advances. It is easy to understand that the control interventions may be a potential source of heterogeneity. We found patients in telehealth-based exercise/physical activity programs gained equivalent effects on pain reduction and physical function with active controls, such as physical therapy and face-to-face exercise, and superior effects than inactive controls, such as usual care and education. Therefore, patients might be inspired by the substantial benefits of telehealth achieved by results with convenient access and at low cost under the condition of constrained medical resources<sup>64</sup>.

Our results updated evidence based on previous systematic review and meta-analysis by Yang et al.<sup>23</sup>, Chen et al.<sup>22</sup>, and McHugh and co-authors<sup>65</sup>. Yang et al.<sup>23</sup> and Chen et al.<sup>22</sup> included nine studies about telehealth-based exercise intervention and 12 RCTs about technology-supported exercise programs reporting up to June, 2021 and August, 2020, respectively. We focused more on the telehealth-based physical activity intervention, and determined the small, but positive effect of telehealth-based exercise /physical activity programs on improvement in physical activity. Our results of physical function and quality of life were positive and in contrast to these two meta-analyses, which might be due to more studies appeared recently. Our subgroup about digital technology was similar to the review by Yang and co-authors<sup>23</sup> that also analysed the delivery technology of telehealth-based programs, reporting seven of nine studies used websites or telephones. Although the review by McHugh and co-authors<sup>65</sup> analyzed the effectiveness of remote exercise programs in reducing knee pain about varied comparators, they only described the difference between inactive comparators and active comparators without quantitative analysis, while we completed an accurate analysis. Moreover, we provided the MIDs of pain, physical activity, and physical function, although the values were below the values of clinical importance.

Although the effectiveness of telehealth-supported exercise/physical activity programs for KOA was proved beneficial in this study, the variation in remote technologies and management of data are still challenges for popularizing and applying for the telehealth-supported exercise/physical activity program as a first-line therapy. Smart wearables, such as smartwatches and smart suits, seem to be the current innovation drivers, that are gradually widely used devices worldwide. Although patients used to be unreceptive to using wearable technologies, the development of this technology increases rapidly, especially for direct-to-consumer wearable tracking technologies<sup>66</sup>, and might increase the acceptance of wearable technologies, and help to facilitate the consistency in remote technologies. The adaption of remote technologies and health information, the fluency of information transmission, the quality and consistency of responses to clients based on the interpretation of individual data, and the cost of exploring new technologies<sup>67</sup> gain more and more focus, and could boost the bloom of telehealth-supported programs.

The key strengths of this study included the investigation of telehealth-supported exercise/physical activity programs on physical activity, and physical function with self-efficacy, to better illustrate the effects of telehealth-supported exercise/physical activity programs. Another strength was the comprehensive systematic component of the literature review, which led to new evidence and identified significant factors that, if concentrated in future research, could facilitate a better understanding and development of telehealth-supported exercise/physical activity programs. There are some limitations in our study. Firstly, although the source of heterogeneity was partially identified, there still was some heterogeneity in the included RCTs for insidious reasons. Secondly, the long-term benefits of telehealth-supported exercise/physical activity program interventions were unknown, as few studies completed a long-term assessment after interventions for more than 3 months. Lastly, it is difficult for researchers to blind allocation for participants and personnel, and this might become another factor contributing to the high heterogeneity.

### 4. Conclusion

This systematic review found low certainty evidence that telehealth-supported exercise/physical activity programs for the treatment of KOA might provide a very small to moderate, and not clinically meaningful improvement in pain intensity, physical activity, and physical function. Additionally, moderate-certainty evidence suggested improvement in quality of life and self-efficacy for pain, and low-certainty evidence suggested an increase in global improvement. But low-certainty evidence suggested that telehealth-supported exercise/physical activity programs made no significant improvement in self-efficacy for physical function. Future research needs to standardize the components of telehealth-supported exercise/physical activity programs and focus more on wearable technologies to provide a high-level of evidence to support clinical practice.

### 5. Methods

The review protocol was registered with PROSPERO (CRD42022359658) and was performed according to the PRISMA recommendations (Preferred Reporting Items for Systematic Reviews and Meta-analyses) <sup>68</sup>.

### Search strategy

In this systematic review and meta-analysis, we searched Embase (via OVID platform), MEDLINE (via OVID platform), CENTRAL (via the Cochrane Library), Web of Science, PubMed, Scopus, and the Physiotherapy Evidence Database from inception to September 2022, for randomized controlled trials (RCTs) published in English language peer-reviewed journals. The specialist register GreyNet (http:// www.greynet.org/) and medRxiv (https://www.medrxiv.org/) were searched for grey literature. The reference lists in studies included for full-text screening were also hand-searched to identify potentially relevant articles. We included studies that intervention group involved telehealth-supported exercise/physical activity programs (including the use of SMS, videos, email, Internet, and applications with or without wearable devices) as the main treatment for KOA patients. The comparator groups included patients who did not receive a telehealth-supported exercise/physical activity intervention. The key search terms included "telerehabilitation", "exercise or physical activity", "knee osteoarthritis", and "randomized controlled trial". We developed a search strategy via OvidSP and the full search strategy is listed in the Supplementary Table 5.

### Eligibility criteria

Studies were included if they met the following inclusion criteria:

Population: participants regardless of age with a diagnosis of KOA.

Intervention: telehealth-supported exercise/physical activity programs delivered by SMS, videos, email, Internet, or applications combined with wearable devices as major intervention.

Comparator: included telehealth-supported programs without exercise or physical activity, or waiting list or non-telemedicine interventions (ie, usual care, conventional exercise programs, patient education, etc.). Control interventions containing telehealth-supported programs with education were not excluded, because achievable exercise/physical activity strategy was omitted.

Outcomes: pain measured by the WOMAC pain subscale, visual analogue scale, Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale, or Numeric Pain Rating Scale, physical activity measured by PASE, time spent in daily moderate-to-vigorous physical activity, International Physical Activity Questionnaire, or International Physical Exercise Questionnaire, and physical function measured by WOMAC function subscale or KOOS function subscale. The secondary outcomes were quality of life measured by KOOS Quality of Life subscale or Assessment of Quality of Life, self-efficacy measured by Arthritis Self-Efficacy Scale pain and function subscale, and overall global improvement.

Study types: randomised controlled trials.

Studies were excluded if they were cases, letters, comments, trial protocols, conference articles, editorials, reviews, or practice guidelines. Articles were excluded if they did not investigate the changes in pain, physical activity, physical function, quality of life, self-efficacy, or global improvement. In addition, studies with other arthritis diseases and unclear statistical analysis or reporting of results were also excluded.

### Selection criteria

Two authors (XNX and ZZW) independently performed the initial screening and study selection according to titles and abstracts. Any disagreements were resolved by a discussion under the guidance of a third reviewer (SYZ). Both reviewers (XNX and ZZW) read the full texts of articles. Conflicts over inclusion were adjudicated by a third reviewer (SYZ).

### Data extraction

Our primary outcomes were pain, physical activity, and physical function. Our secondary outcomes included the quality of life, self-efficacy for pain and function, and global improvement. Two independent authors (ZZW and JYZ) extracted data with a standardized data template. The following data were extracted: country, sampling methodology, sample size, participants' age, detailed telehealth-supported exercise and comparator, time point, the WHO classification of digital health<sup>52</sup>, and statistical reporting of mentioned outcomes. If SDs were missing for continuous data, other statistics (ie, 95% confidence interval, standard errors, *T/F/p*-values, etc.) were used for the calculation of SD via the calculator tool from Review Manager, version 5.4 (Nordic Cochrane Centre, Cochrane Collaboration). Disagreements between the two reviewers were resolved by consensus, and if necessary, by consultation with a third reviewer (XNX).

### Data analysis

Data analysis was performed with Review Manager and R (version 4.2.1). For the continuous variable, Hedges' g (g) with 95% confidence interval (CI) was used for the same measurement across studies for the specified outcomes or not, respectively. Heterogeneity was assessed using Cochrane *Q* statistic (significance level at p < 0.05) and quantified with  $l^2$  (significance level at  $l^2 > 50\%$ )<sup>69,70</sup>. Random effects were used if the *Q* or  $l^2$  value was statistically significant, or a small number of studies were analysed. Otherwise, fixed effects were used. Egger's regression test and funnel plot of the primary outcomes were used to assess the possibility of publication bias<sup>71</sup>. If the test for asymmetry was significant, trim-and-fill method was used to adjust for possible bias by obtaining an estimation of the pooled effect when accounting for missing studies. A sensitivity analysis was performed for primary outcomes to ensure robustness<sup>72</sup>.

A meta-regression test was used for determining the factors which might explain the heterogeneity. The subgroup analysis of the primary outcomes was reported based on: (1) the WHO classification of digital health,<sup>52</sup> (2) the category of telehealth technologies, and (3) the type of treatment (active or inactive interventions) received by control groups. The Hedges' g cut-off points of 0.20, 0.50, and 0.80 can be considered to represent a small, moderate, and large effect, respectively. *P* value < 0.05 was considered statistically significant. MIDs of primary outcomes were calculated on the Hedges' g and pooled represented SDs (pooled from the intervention and control groups in a trial that used the scale)<sup>73</sup>, and compared with reported MIDs. The anchor-based estimates were used if there was no established MID<sup>74</sup>.

### Quality assessment

The Cochrane Collaboration's risk of bias tool was used to assess bias, we assessed each domain, as follows: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other sources of bias. Each component was recorded as low, unclear, or high risk of bias. Additionally, the quality of included studies was measured by the Physiotherapy Evidence Database (PEDro) scale for preciseness.

### Quality of evidence assessment

GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach was used to evaluate the certainty of evidence for each outcome. For each of the outcomes, the overall certainty of evidence for each outcome was graded as high, moderate, low, or very low, and evidence was downgraded by 1 level from high quality for each serious problem found in the domains of risk of bias, inconsistency (substantial heterogeneity:  $l^2 > 50\%$ ), indirectness, imprecision (such as small sample size), and publication bias<sup>75</sup>.

### Declarations

### Author Contributions

CQH, SYZ, and XNX were responsible for concept, study design, and search strategy for this review. XNX and ZZW did all database searching and collating of results. XXN, ZZW, JYZ and SYZ did the article screening, data extraction, and critical appraisal. All authors contributed to conflict resolution during screening. SYZ and XNX were responsible for data curation. XNX, KL, QXC, YWZ and FSX contributed to data analysis and data interpretation. XNX and SYZ drafted the manuscript. All authors contributed to reviewing and editing of the final manuscript.

### Acknowledgments

We thank the Qing-Yang Shi in West China Hospital for methodology assistance.

### Funding

This study supported by the National Natural Science Foundation of China (81972146; 82002393; 82272599), the Department of Science and Technology of Sichuan Province (2021YFS0004; 2021YJ0424), West China Hospital of Sichuan University (2019HXBH058), and China Postdoctoral Science Foundation (2020M673251). The funders played no role in the design, conduct, or reporting of this study.

Competing Interests statement

We declare no competing interests.

### Data sharing

All data for this review and meta-analysis were obtained from primary literature. Data extracted and derived data will be made available on reasonable request from the first or corresponding author.

### References

- 1. Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. The Lancet 393, 1745–1759, doi:10.1016/s0140-6736(19)30417-9 (2019).
- 2. Kolasinski, S. L. *et al.* 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care Res (Hoboken)* 72, 149–162, doi:10.1002/acr.24131 (2020).
- 3. Nguyen, U.-S. D. T. *et al.* Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Annals of Internal Medicine **155**, 725–732, doi:10.7326/0003-4819-155-11-201112060-00004 (2011).

- 4. Vollset, S. E. *et al.* Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. Lancet **396**, 1285–1306, doi:10.1016/s0140-6736(20)30677-2 (2020).
- 5. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet **392**, 1789–1858, doi:10.1016/s0140-6736(18)32279-7 (2018).
- 6. Safiri, S. *et al.* Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis **79**, 819–828, doi:10.1136/annrheumdis-2019-216515 (2020).
- 7. Abbasi, J. Can Exercise Prevent Knee Osteoarthritis? JAMA 318, 2169-2171, doi:10.1001/jama.2017.16144 (2017).
- 8. Abramoff, B. & Caldera, F. E. Osteoarthritis: Pathology, Diagnosis, and Treatment Options. Med Clin North Am **104**, 293–311, doi:10.1016/j.mcna.2019.10.007 (2020).
- 9. Witjes, S. *et al.* Return to Sports and Physical Activity After Total and Unicondylar Knee Arthroplasty: A Systematic Review and Meta-Analysis. Sports Medicine (Auckland, N.Z.) **46**, 269–292, doi:10.1007/s40279-015-0421-9 (2016).
- 10. Barnett, R. Osteoarthritis. Lancet 391, 1985, doi:10.1016/s0140-6736(18)31064-x (2018).
- 11. Bijlsma, J. W., Berenbaum, F. & Lafeber, F. P. Osteoarthritis: an update with relevance for clinical practice. Lancet **377**, 2115–2126, doi:10.1016/s0140-6736(11)60243-2 (2011).
- 12. Biver, E. *et al.* Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Res Rev 55, 100946, doi:10.1016/j.arr.2019.100946 (2019).
- 13. Bannuru, R. R. *et al.* OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27, 1578–1589, doi:10.1016/j.joca.2019.06.011 (2019).
- Allen, K. D., Golightly, Y. M. & White, D. K. Gaps in appropriate use of treatment strategies in osteoarthritis. Best Practice & Research. Clinical Rheumatology 31, 746–759, doi:10.1016/j.berh.2018.05.003 (2017).
- 15. Petursdottir, U., Arnadottir, S. A. & Halldorsdottir, S. Facilitators and barriers to exercising among people with osteoarthritis: a phenomenological study. Physical Therapy **90**, 1014–1025, doi:10.2522/ptj.20090217 (2010).
- 16. Nicolson, P. J. A., Hinman, R. S., Kasza, J. & Bennell, K. L. Trajectories of adherence to home-based exercise programs among people with knee osteoarthritis. Osteoarthritis and Cartilage **26**, 513–521, doi:https://doi.org/10.1016/j.joca.2018.01.009 (2018).
- 17. Tuckson, R. V., Edmunds, M. & Hodgkins, M. L. Telehealth. N Engl J Med 377, 1585–1592, doi:10.1056/NEJMsr1503323 (2017).
- 18. What Is Telehealth. NEJM Catalyst, doi:10.1056/CAT.18.0268.
- 19. Monaghesh, E. & Hajizadeh, A. The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence. BMC Public Health 20, 1193, doi:10.1186/s12889-020-09301-4 (2020).
- 20. George, M. D. *et al.* Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. Arthritis Care Res (Hoboken) **73**, 1153–1161, doi:10.1002/acr.24626 (2021).
- 21. Xie, S. H. *et al.* Effect of Internet-Based Rehabilitation Programs on Improvement of Pain and Physical Function in Patients with Knee Osteoarthritis: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res 23, e21542, doi:10.2196/21542 (2021).
- 22. Chen, T., Or, C. K. & Chen, J. Effects of technology-supported exercise programs on the knee pain, physical function, and quality of life of individuals with knee osteoarthritis and/or chronic knee pain: A systematic review and meta-analysis of randomized controlled trials. J Am Med Inform Assoc 28, 414–423, doi:10.1093/jamia/ocaa282 (2021).
- 23. Yang, Y. et al. Effectiveness of telehealth-based exercise interventions on pain, physical function and quality of life in patients with knee osteoarthritis: A meta-analysis. J Clin Nurs, doi:10.1111/jocn.16388 (2022).
- 24. Östlind, E., Eek, F., Stigmar, K., Sant'Anna, A. & Hansson, E. E. Promoting work ability with a wearable activity tracker in working age individuals with hip and/or knee osteoarthritis: a randomized controlled trial. BMC Musculoskeletal Disorders 23, 112, doi:10.1186/s12891-022-05041-1 (2022).
- 25. Bennell, K. L. *et al.* Comparing Video-Based, Telehealth-Delivered Exercise and Weight Loss Programs With Online Education on Outcomes of Knee Osteoarthritis: A Randomized Trial. Ann Intern Med **175**, 198–209, doi:10.7326/M21-2388 (2022).
- 26. Egerton, T., Bennell, K. L., McManus, F., Lamb, K. E. & Hinman, R. S. Comparative effect of two educational videos on self-efficacy and kinesiophobia in people with knee osteoarthritis: an online randomised controlled trial. Osteoarthritis Cartilage, doi:10.1016/j.joca.2022.05.010 (2022).
- 27. Alasfour, M. & Almarwani, M. The effect of innovative smartphone application on adherence to a home-based exercise programs for female older adults with knee osteoarthritis in Saudi Arabia: a randomized controlled trial. Disabil Rehabil 44, 2420–2427, doi:10.1080/09638288.2020.1836268 (2022).
- 28. Thiengwittayaporn, S. *et al.* Development of a mobile application to improve exercise accuracy and quality of life in knee osteoarthritis patients: a randomized controlled trial. Arch Orthop Trauma Surg, doi:10.1007/s00402-021-04149-8 (2021).
- 29. Rafiq, M. T., Abdul Hamid, M. S. & Hafiz, E. The effect of rehabilitation protocol using mobile health in overweight and obese patients with knee osteoarthritis: a clinical trial. Adv Rheumatol **61**, 63, doi:10.1186/s42358-021-00221-4 (2021).
- Nelligan, R. K., Hinman, R. S., Kasza, J., Crofts, S. J. C. & Bennell, K. L. Effects of a Self-directed Web-Based Strengthening Exercise and Physical Activity Program Supported by Automated Text Messages for People With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA Intern Med 181, 776–785, doi:10.1001/jamainternmed.2021.0991 (2021).
- 31. Hsu, Y. I., Chen, Y. C., Lee, C. L. & Chang, N. J. Effects of Diet Control and Telemedicine-Based Resistance Exercise Intervention on Patients with Obesity and Knee Osteoarthritis: A Randomized Control Trial. Int J Environ Res Public Health 18, doi:10.3390/ijerph18157744 (2021).

- 32. Arfaei Chitkar, S. S. *et al.* The effect of mobile-app-based instruction on the physical function of female patients with knee osteoarthritis: a parallel randomized controlled trial. BMC Womens Health **21**, 333, doi:10.1186/s12905-021-01451-w (2021).
- 33. Allen, K. D. *et al.* Stepped Exercise Program for Patients With Knee Osteoarthritis: A Randomized Controlled Trial. Ann Intern Med **174**, 298–307, doi:10.7326/M20-4447 (2021).
- Allen, K. D. *et al.* Physical therapy vs internet-based exercise training for patients with knee osteoarthritis: results of a randomized controlled trial. Osteoarthritis Cartilage 26, 383–396, doi:10.1016/j.joca.2017.12.008 (2018).
- 35. Azma, K., RezaSoltani, Z., Rezaeimoghaddam, F., Dadarkhah, A. & Mohsenolhosseini, S. Efficacy of tele-rehabilitation compared with office-based physical therapy in patients with knee osteoarthritis: A randomized clinical trial. J Telemed Telecare 24, 560–565, doi:10.1177/1357633X17723368 (2018).
- Baker, K. *et al.* Efficacy of Computer-Based Telephone Counseling on Long-Term Adherence to Strength Training in Elderly Patients With Knee Osteoarthritis: A Randomized Trial. Arthritis Care Res (Hoboken) 72, 982–990, doi:10.1002/acr.23921 (2020).
- 37. Bennell, K. *et al.* Behavior Change Text Messages for Home Exercise Adherence in Knee Osteoarthritis: Randomized Trial. J Med Internet Res 22, e21749, doi:10.2196/21749 (2020).
- Bennell, K. L. et al. Telephone Coaching to Enhance a Home-Based Physical Activity Program for Knee Osteoarthritis: A Randomized Clinical Trial. Arthritis Care Res (Hoboken) 69, 84–94, doi:10.1002/acr.22915 (2017).
- Bennell, K. L. *et al.* Effectiveness of an Internet-Delivered Exercise and Pain-Coping Skills Training Intervention for Persons With Chronic Knee Pain: A Randomized Trial. Ann Intern Med 166, 453–462, doi:10.7326/M16-1714 (2017).
- 40. Bennell, K. L. *et al.* Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis: A Randomized Clinical Trial. Ann Intern Med, doi:10.7326/M22-1761 (2022).
- 41. Gohir, S. A., Eek, F., Kelly, A., Abhishek, A. & Valdes, A. M. Effectiveness of Internet-Based Exercises Aimed at Treating Knee Osteoarthritis: The iBEAT-OA Randomized Clinical Trial. JAMA Netw Open 4, e210012, doi:10.1001/jamanetworkopen.2021.0012 (2021).
- 42. Hinman, R. S. *et al.* Does telephone-delivered exercise advice and support by physiotherapists improve pain and/or function in people with knee osteoarthritis? Telecare randomised controlled trial. Br J Sports Med **54**, 790–797, doi:10.1136/bjsports-2019-101183 (2020).
- 43. Li, L. C. *et al.* Effects of a 12-Week Multifaceted Wearable-Based Program for People With Knee Osteoarthritis: Randomized Controlled Trial. JMIR Mhealth Uhealth 8, e19116, doi:10.2196/19116 (2020).
- 44. Mecklenburg, G., Smittenaar, P., Erhart-Hledik, J. C., Perez, D. A. & Hunter, S. Effects of a 12-Week Digital Care Program for Chronic Knee Pain on Pain, Mobility, and Surgery Risk: Randomized Controlled Trial. J Med Internet Res 20, e156, doi:10.2196/jmir.9667 (2018).
- 45. O'Brien, K. M. *et al.* Telephone-based weight loss support for patients with knee osteoarthritis: a pragmatic randomised controlled trial. Osteoarthritis Cartilage **26**, 485–494, doi:10.1016/j.joca.2018.01.003 (2018).
- 46. Odole, A. C. & Ojo, O. D. A Telephone-based Physiotherapy Intervention for Patients with Osteoarthritis of the Knee. Int J Telerehabil 5, 11–20, doi:10.5195/ijt.2013.6125 (2013).
- 47. Odole, A. C. & Ojo, O. D. Is telephysiotherapy an option for improved quality of life in patients with osteoarthritis of the knee? *Int J Telemed Appl* 2014, 903816, doi:10.1155/2014/903816 (2014).
- 48. Skrepnik, N. *et al.* Assessing the Impact of a Novel Smartphone Application Compared With Standard Follow-Up on Mobility of Patients With Knee Osteoarthritis Following Treatment With Hylan G-F 20: A Randomized Controlled Trial. JMIR Mhealth Uhealth **5**, e64, doi:10.2196/mhealth.7179 (2017).
- 49. Messier, S. P. *et al.* Effect of High-Intensity Strength Training on Knee Pain and Knee Joint Compressive Forces Among Adults With Knee Osteoarthritis: The START Randomized Clinical Trial. JAMA **325**, 646–657, doi:10.1001/jama.2021.0411 (2021).
- 50. Dupont, J. *et al.* Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years). J Cachexia Sarcopenia Muscle **12**, 1818–1831, doi:10.1002/jcsm.12785 (2021).
- 51. Kim, M. S. *et al.* The Minimal Clinically Important Difference (MCID) for the WOMAC and Factors Related to Achievement of the MCID After Medial Opening Wedge High Tibial Osteotomy for Knee Osteoarthritis. Am J Sports Med **49**, 2406–2415, doi:10.1177/03635465211016853 (2021).
- 52. World Health, O. Classification of digital health interventions v1.0: a shared language to describe the uses of digital technology for health. (World Health Organization, Geneva, 2018).
- 53. Williams, D. M. Outcome Expectancy and Self-Efficacy: Theoretical Implications of an Unresolved Contradiction. Personality and Social Psychology Review 14, 417–425, doi:10.1177/1088868310368802 (2010).
- 54. Rausch Osthoff, A. K. *et al.* Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis. RMD Open *4*, e000713, doi:10.1136/rmdopen-2018-000713 (2018).
- 55. Mosnaim, G. S. *et al.* The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial. J Allergy Clin Immunol Pract **9**, 1586–1594, doi:10.1016/j.jaip.2020.10.064 (2021).
- 56. Gask, L. Role of specialists in common chronic diseases. BMJ 330, 651-653 (2005).
- 57. Palamara, K. *et al.* Impact of a Virtual Professional Development Coaching Program on the Professional Fulfillment and Well-Being of Women Surgery Residents: A Randomized Controlled Trial. Ann Surg, doi:10.1097/SLA.00000000005562 (2022).
- 58. Sieczkowska, S. M. *et al.* Health Coaching Strategies for Weight Loss: A Systematic Review and Meta-Analysis. Adv Nutr **12**, 1449–1460, doi:10.1093/advances/nmaa159 (2021).
- 59. Wilhelm, S. *et al.* Efficacy of App-Based Cognitive Behavioral Therapy for Body Dysmorphic Disorder with Coach Support: Initial Randomized Controlled Clinical Trial. Psychother Psychosom **91**, 277–285, doi:10.1159/000524628 (2022).

- 60. Mahmud, N. *et al.* Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial. JAMA Netw Open **4**, e2034553, doi:10.1001/jamanetworkopen.2020.34553 (2021).
- 61. Mehta, S. J. *et al.* Effect of Remote Monitoring on Discharge to Home, Return to Activity, and Rehospitalization After Hip and Knee Arthroplasty: A Randomized Clinical Trial. JAMA Netw Open **3**, e2028328, doi:10.1001/jamanetworkopen.2020.28328 (2020).
- 62. Masuki, S., Morikawa, M. & Nose, H. Internet of Things (IoT) System and Field Sensors for Exercise Intensity Measurements. Compr Physiol **10**, 1207–1240, doi:10.1002/cphy.c190010 (2020).
- 63. Kurtz, S. M. *et al.* Patient Perceptions of Wearable and Smartphone Technologies for Remote Outcome Monitoring in Patients Who Have Hip Osteoarthritis or Arthroplasties. J Arthroplasty **37**, doi:10.1016/j.arth.2022.02.026 (2022).
- 64. Duffy, S. & Lee, T. H. In-Person Health Care as Option B. N Engl J Med 378, 104–106, doi:10.1056/NEJMp1710735 (2018).
- 65. McHugh, C. G., Kostic, A. M., Katz, J. N. & Losina, E. Effectiveness of remote exercise programs in reducing pain for patients with knee osteoarthritis: A systematic review of randomized trials. Osteoarthritis and Cartilage Open 4, doi:10.1016/j.ocarto.2022.100264 (2022).
- 66. Fogel, A. L. & Kvedar, J. C. Reported Cases of Medical Malpractice in Direct-to-Consumer Telemedicine. JAMA **321**, 1309–1310, doi:10.1001/jama.2019.0395 (2019).
- 67. Romanick-Schmiedl, S. & Raghu, G. Telemedicine maintaining quality during times of transition. Nat Rev Dis Primers **6**, 45, doi:10.1038/s41572-020-0185-x (2020).
- 68. Liberati, A. *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ **339**, b2700, doi:10.1136/bmj.b2700 (2009).
- Hoit, G., Whelan, D. B., Dwyer, T., Ajrawat, P. & Chahal, J. Physiotherapy as an Initial Treatment Option for Femoroacetabular Impingement: A Systematic Review of the Literature and Meta-analysis of 5 Randomized Controlled Trials. Am J Sports Med 48, 2042–2050, doi:10.1177/0363546519882668 (2020).
- Takeshima, N. et al. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Med Res Methodol 14, 30, doi:10.1186/1471-2288-14-30 (2014).
- 71. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ **315**, 629–634, doi:10.1136/bmj.315.7109.629 (1997).
- 72. Patsopoulos, N. A., Evangelou, E. & Ioannidis, J. P. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol **37**, 1148–1157, doi:10.1093/ije/dyn065 (2008).
- 73. Murad, M. H., Wang, Z., Chu, H. & Lin, L. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ **364**, k4817, doi:10.1136/bmj.k4817 (2019).
- 74. Devji, T. *et al.* Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ **369**, m1714, doi:10.1136/bmj.m1714 (2020).
- 75. Ebadi, S. *et al.* Therapeutic ultrasound for chronic low back pain. *Cochrane Database Syst Rev* **7**, CD009169, doi:10.1002/14651858.CD009169.pub3 (2020).

### **Tables**

Table 1. Characteristics of included Studies

	Country	Sample size (subjects in telehealth)	Age (yrs), mean±SD, I vs. C	Female (%)	Intervention	Types of telehealth	Models of delivery	Intervention time (weeks)	Comparate
Alasfour M et al. 2022	Saudi Arabia	40 (20)	53.7±4.0 vs. 55.2±4.6	100	Isometric/isotonic quadriceps exercise plus remote monitoring	Mobile app	In-person	б	Same exercise pl paper materials
Allen KD et al. 2018	United States	350 (142)	65.3±11.5 vs. 65.7±10.3 vs. 64.3±12.2	71.7	Self-directed exercise and reminders plus remote monitoring	Internet	No interacting contacts	48	An appropriat home exercise program, F and wait li
Allen KD et al. 2021	America	345 (230)	59.9±9.9 vs. 60.2±11.1	15.4	Exercise, PA, and PT plus coaching	Internet and telephone	No interacting contacts Virtual contact	36	Education via mail
Arfaei Chitkar SS et al. 2021	Iran	60 (31)	57.8±8.6 vs. 58.5±6.3	100.0	How to increase PA	Mobile app	No interacting contacts	8	Education via face to face
Baker K et al. 2020	Massachusetts	104 (52)	65.8±6.6 vs. 64.5±8.3	81.7	Exercise, reminder plus remote coaching and monitoring	Telephone	Virtual contact In-Person	96	Exercise a automated phone message reminder
Bennell KL et al. 2017 (A)	Australia	168 (84)	61.1±6.9 vs. 63.4±7.8	63.1	Exercise, education, and PA intervention by physical therapist plus telephone coaching and monitoring	Telephone	Virtual contact In-Person	24	Exercise, education, and PA interventio by physica therapist
Bennell KL et al. 2017 (B)	United States	148 (74)	60.8±6.5 vs. 61.5±7.6	56.1	Exercise, education, and PA intervention plus telephone coaching and monitoring	Internet	Virtual contact	36	Education
Bennell KL et al. 2020	Australia	110 (56)	61.7±6.7 vs. 62.9±6.8	67.3	Self-directed exercise and reminders	SMS	No interacting contacts	24	Self-direct Exercise program advised by physical therapists
Bennell KL et al. 2022 (A)	Australia	415 (347)	65.4±8.2 vs. 64.1±8.1 vs. 65.3±8.3	54.7	Exercise, tele- education, PA, and self-management plus remote coaching and monitoring	Internet and wearables	Virtual contact	24	Tele-exerci and tele- education diet and te education
Bennell KL et al.	Australia	212 (107)	62.8±8.2	69.8	Exercise and tele-	Internet	No	12	Tele-

2022 (B)			vs. 61.8±7.2		education plus reminder		interacting contacts		education
Egerton T et al. 2022	Australia	589 (296)	median (IQR):55 (50-62) vs. 54 (50-61)	65.9	How to increase PA	Internet access videos	No interacting contacts	12 min	Education
Gohir SA et al. 2021	England	105 (48)	65.2±9.7 vs. 68.0±8.6	67.1	Exercise and education plus remote reminder and monitoring	Mobile app	Virtual contact	б	Usual care
Hinman RS et al. 2020	Australia	175 (87)	62.4±9.1 vs. 62.5±8.1	629	Exercise, education, and how to increase PA plus coaching or not	Telephone and Internet	Virtual contact	24	Education
Hsu YI et al. 2021	China	66 (22)	65.6±3.9 vs. 64.2±4.1 vs. 66.0±3.9	60.6	Exercise plus remote monitoring and coaching	Telephone and Internet	Virtual contact	12	Self- managem
Li LC et al. 2020	Canada	51 (26)	65.0±8.0 vs. 64.8±9.0	82.4	Education and how to PA plus remote monitoring coaching	Telephone, wearables, and Internet	Virtual contact	12	Waiting lis
							In-Person		
Nelligan RK et al. 2021	Australia	206 (103)	60.3±8.2 vs. 59.0±8.5	61.2	Exercises, and how to increase PA plus remote reminders	Internet and Mobile app	No interacting contacts	24	Education
O'Brien KM et al. 2018	Australia	119 (59)	63.0±11.1 vs 60.2±13.9	62.2	How to increase PA and self- management plus coaching	Internet and telephone	Virtual contact	24	Usual care
Odole AC et al. 2013	Nigeria	50 (25)	56.0±7.4 vs. 55.0 ± 7.8	48.0	Exercise plus remote monitoring and coaching	Telephone	Virtual contact	6	Exercise
Rafiq MT et al. 2021	England	114 (76)	53.5±4.4 vs. 54.0±4.4 vs. 52.9±4.6	56.1	Exercise and education plus remote reminder or not	SMS	Virtual contact	12	Education
Thiengwittayaporn S et al. 2021	Thailand	82 (40)	62.2±6.8 vs. 63.0±9.7	89.0	Exercise and education plus remote monitoring	Mobile app	No interacting contacts	4	Education handout
Azma K et al. 2018	Iran	54 (27)	55±5.2 vs. 56±5.1	60.2	Exercises, education, and hot pack plus remote reminder and coaching	Telephone	Virtual contact In-Person	6	Hot pack, face-to-fac exercises and education

Odole AC et al. 2014	Nigeria	50 (25)	56.0±7.4 vs. 55.0±7.8	48.0	Exercise plus remote coaching	Mobile app and telephone	Virtual contact	6	Exercise
Skrepnik N et al. 2017	United States	211 (107)	61.6±9.5 vs. 63.6±9.3	50.2	How to increase PA plus remote monitor	Mobile app and wearable activity monitor	No interacting contacts	12	How to increase P

I = intervention group. C = control group. PA = physical activity


Table 2. Meta-analysis results of the primary effects of telehealth-based exercise/physical activity programs

	Number of RCTs	g (95% Cl)	P value of Egger's Regression Test	Calculated MID	Reported MID	Quality of Evidence (GRADE)
Pain	19	-0.39 (-0.67 to -0.11)	0.4125	1.3	2.0	$\oplus \oplus \ominus \ominus$
Physical activity	9	0.13 (0.03 to 0.23)	0.4586	9.0	46.0	$\oplus \oplus \ominus \ominus$
Physical function	18	-0.51 (-0.98 to -0.05)	0.1921	5.3	10.1	$\oplus \oplus \ominus \ominus$

MID = minimal important difference


### **Figures**

Figure 1: Study selection



See image above for figure legend.

Figure 2: Forest plot of pain, physical activity, and physical function



#### Figure 2

See image above for figure legend.

## Figure 3: Subgroup analysis of pain and physical function based on the WHO classification Pain

Study		Mean	rograms SD	Total	Mean	Control SD	Standardised Mean Difference	SMD	959	6-CI	Weig
						50			-07		
Interventions for clients and h Alasfour M et al. 2022	18		1.8300	17	-0.82	2.1300		-0.69	[-1.38, -0	011	4.4
Baker K et al. 2020	52	-0.80		52	-0.62	3.6800	<u> </u>		[-0.43, 0		5.4
Bennell KL et al. 2017 (A)	72	-2.50		70	-2.00				1-0.58. 0		5.5
Bennell KL et al. 2017 (B)	66	-2.50	1.9300	67	-1.50		1		[-0.83, -0		5.5
Bennell KL et al. 2022 (A)	172	-2.60	1.6800	67	-1.70	1.8400	4	-0.40	[-0.81; -0	231	5.6
Gohir SA et al. 2021	48			82	-0.30			0.32	[-1.14; -0	401	5.4
Hinman RS et al. 2020	83	2.50	1.8700	82		1.9500		0.76	[-0.67; -0	061	5.6
Li LC et al. 2020	24		14.4800	24		14.7400	1	0.02	[-0.59, 0	661	4 8
O'Brien KM et al. 2018	59		2.2400	60		2.5000			[-0.11, 0		5.5
Thiengwittayaporn S et al. 2021	42		7.0100	40	1.40	5.9000			[-0.45, 0		5.3
Random effects model	636	1.50	7.0100	561	1.40	3.9000	0	-0.29	[-0.49; -0	.09]	53.1
Heterogeneity: $I^2 = 63\%$ , $\tau^2 = 0.0646$	5. p < 0	.01									
Interventions for clients											
Allen KD et al. 2018	142	-1.12	3.2500	208	-0.69	3.2300		-0.13	[-0.35; 0	081	5.8
Allen KD et al. 2021	163	-1.00	3.2600	94	0.40	3 4600	+		[-0.68, -0		5.7
Arfaei Chitkar SS et al. 2021	31	-6.65	4.5800	29	-3.35	1.5900			[-1.470		4.9
Bennell KL et al. 2020	48		2.1500	49	0.20				1-0.22 0		5.4
Bennell KL et al. 2022 (B)	107		2.3000	105	-1.40	2.4000	-		(-0.52; 0		5.7
Nelligan RK et al. 2021	91		1.9500	92		2.1000	-		[-1.09: -0		5.6
Rafig MT et al. 2021	32		0.8700	32	-0.28		II	-3 02	1-3.752	291	4.3
Random effects model	614	2.10	0.01.00	609	0.20	0.1 100			[-1.47; 0		37.4
Heterogeneity: $l^2 = 92\%$ , $\tau^2 = 0.9523$		01							, .		
interventions for healthcare p	rovide	ins.									
Hsu YI et al. 2021			1.7900	21	-2.15	1,9900		0.12	[-0.48; 0	731	4.7
Odole AC et al. 2013			16.5600			16.9900		0.28	1-0.28. 0	831	4.9
Random effects model	46	-32.20	10.0000	46	-37.00	10.3300			[-0.20; 0		9.6
Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 0$				40				0.21	1-0.20, 0	.orl	0.0
Random effects model	1296			1216			1				
Random enects model				1210				-0.39	[-0.67; -0	au	100.0
Heterogeneity: $l^2 = 83\%$ , $\tau^2 = 0.349i$ Test for overall effect: $z = -2.70$ (p <	s, p < 0	1.01									
							-3 -2 -1 0 1 2 3				
Test for subgroup differences: $\chi_2^2 = -$ <b>rysical function</b>	6.48, df						← →	•			
Test for subgroup differences: $\chi_2^2 = 1$ <b>nysical function</b> Telehealth-supporte	6 48, df d exer	rcise pr	ograms	Total		Control	Standardised Mean	euro	0.5%	CL	Weight
Test for subgroup differences: $\chi_2^2 = 1$ <b>nysical function</b> Telehealth-supporte	6 48, df d exer		ograms	Total	Mean	Control SD	Standardised Mean Difference	SMD	95%	-CI	Weigh
Test for subgroup differences: z <sub>2</sub> <sup>2</sup> = 1 nysical function Telehealth-supporte Study Interventions for clients and	6.48, df d exer Total i healt	ncise pr Mean thcare p	ograms SD providers		Mean	SD					
Test for subgroup differences: $\chi^2_2$ = <b>nysical function</b> Telehealth-supporte Study Interventions for clients and Alasfour M et al. 2022	6 48, df d exer Total i healt 18	Mean Mean thcare p -5.11	ograms SD providers 3.1400	17	Mean	SD 3.1000		-1.20	[-1.92; -0	.47]	5.19
Test for subgroup differences: $\chi_2^2 = 1$ nysical function Telehealth-supporte Study Interventions for clients and Alasfour M et al. 2022 Baker K et al. 2020	d exer Total 18 52	Mean Mean thcare p -5.11 -0.46	ograms SD aroviders 3.1400 10.5300	17 52	Mean -1.29 -0.01	3.1000 10.6100		-1.20	[-1.92; -0. [-0.43; 0	.47]	5.19
Test for subgroup differences: $\chi^2_2$ = <b>nysical function</b> Telehealth-supporte Study Interventions for clients and Alasfour M et al. 2022	d exer Total 18 52	Mean Mean thcare p -5.11 -0.46	ograms SD providers 3.1400	17 52	Mean -1.29 -0.01	SD 3.1000		-1.20	[-1.92; -0	.47]	5.19
Test for subgroup differences: $\chi_2^2 = 1$ nysical function Telehealth-supporte Study Interventions for clients and Alasfour M et al. 2022 Baker K et al. 2020	d exer Total 1 healt 18 52 72	mean Mean -5.11 -0.46 -12.60	ograms SD aroviders 3.1400 10.5300	17 52	-1.29 -0.01 -12.10	3.1000 10.6100		-1.20 -0.04 -0.05	[-1.92; -0. [-0.43; 0	.47] .34] .28]	5.19 5.79 5.79
Test for subgroup differences: $y_0^2$ = <b>tysical function</b> <b>Telehealth-supporte</b> <b>Study</b> Interventions for clients and Alasfour M et al. 2022 Baker K et al. 2027 (A)	6 48, df d exer Total i healt 18 52 72 66	Mean Mean -5.11 -0.46 -12.60 -14.40	ograms SD 3.1400 10.5300 10.8600	17 52 70	-1.29 -0.01 -12.10 -6.80	3.1000 10.6100 10.9900		-1.20 -0.04 -0.05 -0.77	[-1.92; -0 [-0.43; 0 [-0.37; 0	.47] .34] .28] .42]	5.19 5.79 5.79 5.79
Test for subgroup differences: $y_2^2 = i$ <b>sysical function</b> <b>Telehealth-supporte</b> <b>Study</b> Interventions for clients and Alasfour M et al. 2002 Bennel K., et al. 2001 (A) Bennel K., et al. 2017 (A)	6 48, df d exer Total 18 52 72 66 172	rcise pr Mean +5.11 -0.46 -12.60 -14.40 -10.00	ograms SD 3.1400 10.5300 10.8600 9.3000	17 52 70 67	-1.29 -0.01 -12.10 -6.80 -2.90	3.1000 10.6100 10.9900 10.3500		-1.20 -0.04 -0.05 -0.77 -0.70	[-1.92; -0. [-0.43; 0 [-0.37; 0 [-1.12; -0	.47] .34] .28] .42] .41]	5.19 5.79 5.79 5.79 5.89
Test for subgroup differences: $y_0^2$ = <b>tysical function</b> <b>Telehealth-supporte</b> <b>Study</b> Interventions for clients and Alasfour M et al. 2022 Baker K et al. 2022 Bennel KL, et al. 2017 (A) Bennel KL, et al. 2027 (B) Bennel KL, et al. 2022 (B)	6 48, df d exer Total 18 52 72 66 172 48	rcise pr Mean -5.11 -0.46 -12.60 -14.40 -10.00 -7.80	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000	17 52 70 67 67	-1.29 -0.01 -12.10 -6.80 -2.90 -4.30	3.1000 10.6100 10.9900 10.3500 10.2500		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49	[-1.92; -0. [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0	.47] .34] .28] .42] .41] .10]	5.19 5.79 5.79 5.79 5.89 5.89
Test for subgroup differences: $v_{2}^{2} = 1$ <b>sysical function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients ant</b> Alasfour M et al. 2022 Bennel KL et al. 2017 (A) Bennel KL et al. 2017 (A) Bennel KL et al. 2017 (A) Bennel KL et al. 2022 (A) Cohir SA et al. 2021	6 48, df d exer Total 18 52 72 66 172 48 83	thcare p -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90	ograms SD providers 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600	17 52 70 67 67 57	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44	[-1.92; -0. [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0 [-0.88; -0 [-0.75; -0	.47] .34] .28] .42] .41] .10] .13]	5.19 5.79 5.79 5.79 5.79 5.79 5.79
Test tor subgroup differences: $v_{0}^{2} = 1$ <b>tysical function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> Alasfour M et al. 2022 Banar K et al. 2020 Bennel KL et al. 2020 Bennel KL et al. 2021 Bennel KL et al. 2022 ( Gehirr SA et al. 2021) Himman R5 et al. 2021	6 48, df d exer Total 18 52 72 66 172 48 83	thcare p -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600 10.7500	17 52 70 67 67 57 82	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 0.09	[-1.92; -0. [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0. [-0.88; -0	.47] .34] .28] .42] .41] .10] .13] .66]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.49
Test for subgroup differences: $v_2^2$ = nysical function Telehealth-supporte Study Interventions for clients and Alasfour M et al. 2022 Bennel KL et al. 2017 (A) Bennel KL et al. 2017 (A) Bennel KL et al. 2017 (A) Bennel KL et al. 2021 Himman RS et al. 2020 Himman RS et al. 2020	6 48, df d exer Total 1 healt 18 52 72 66 172 48 83 24	thcare p -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600 10.7500 13.9700	17 52 70 67 67 57 82 24	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 16.3800		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 0.09 0.24	[-1.92; -0 [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0 [-0.88; -0 [-0.75; -0 [-0.48; 0 [-0.18; 0	.47] .34] .28] .42] .41] .10] .13] .66] .67]	5.19 5.79 5.79 5.79 5.89 5.79 5.79 5.79 5.79 5.79 5.49 5.69
Test for subgroup differences $\chi_2^2$ = aysical function Telehealth-supports Study Interventions for clients and Alasdour M et al. 2002 Bennel KL, et al. 2017 (A) Bennel KL, et al. 2017 (A) Bennel KL, et al. 2017 (A) Gehr SA et al. 2022 (A) Gehr SA et al. 2022 (A) Gehr SA et al. 2020 (C) Himman RS et al. 2020 (A) C) Himman RS et al. 2020 (A) (C) Himman RS et al.	d exer Total 1 healt 18 52 72 66 172 48 83 24 37 572	rcise pr Mean +5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50 1.60	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600 10.7500 13.9700	17 52 70 67 67 57 82 24 51	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 16.3800		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 0.09 0.24	[-1.92; -0 [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0 [-0.88; -0 [-0.75; -0 [-0.48; 0	.47] .34] .28] .42] .41] .10] .13] .66] .67]	5.19 5.79 5.79 5.79 5.89 5.79 5.79 5.79 5.79 5.79 5.49 5.69
Test for subgroup differences $\chi_{2}^{2} = 1$ <b>sysical function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> Association of the supporter Study <b>Interventions</b> for clients and Association of the support Bennel KL, et al. 2017 (A) Bennel KL, et al. 2017	d exer Total 1 healt 18 52 72 66 172 48 83 24 37 572	rcise pr Mean +5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50 1.60	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600 10.7500 13.9700	17 52 70 67 67 57 82 24 51	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 16.3800		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 0.09 0.24	[-1.92; -0 [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0 [-0.88; -0 [-0.75; -0 [-0.48; 0 [-0.18; 0	.47] .34] .28] .42] .41] .10] .13] .66] .67]	5.19 5.79 5.79 5.79 5.89 5.79 5.79 5.79 5.79 5.79 5.49 5.69
Test for subgroup differences $z_{0}^{2}$ = 1 <b>sysical function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> Radsfort M et al. 2020 Raker K et al. 2020 Raker K et al. 2020 Bennel KL, et al. 2021 (A) Bennel KL, et al. 2021 (A) Bennel KL, et al. 2021 (A) Celler SA et al. 2022 (A) Celler SA et al. 2022 (A) Celler SA et al. 2021 (L) Cell al. 2020 O'Bennel KL et al. 2021 O'Bennel KL et al. 2021 O'Bennel KL et al. 2021 O'Bennel KL et al. 2021 O'Bennel KL et al. 2021 Celler SA et al. 2021 Ce	d exer Total 1 healt 18 52 72 66 172 48 83 24 37 <b>572</b> 293, p	rcise pr Mean -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50 1.60	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600 10.7500 13.9700	17 52 70 67 67 57 82 24 51 487	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 16.3800		-1.20 -0.04 -0.05 -0.70 -0.70 -0.49 -0.44 0.09 0.24 <b>-0.36</b>	[-1.92; -0 [-0.43; 0 [-0.37; 0 [-1.12; -0 [-0.99; -0 [-0.88; -0 [-0.75; -0 [-0.48; 0 [-0.18; 0	.47] .34] .28] .42] .41] .10] .13] .66] .67] .08]	5.15 5.75 5.75 5.75 5.75 5.75 5.75 5.75
Test for subgroup differences $x_2^2 = 1$ ysical function Telefaalta-supporte Study Interventions for clients and Ausford M et al. 2020 Balenc K et al. 2020 Balenc K et al. 2020 Bernens RL, et al. 2021 Himman RS et al. 2022 Himman RS et al. 2022 Himman RS et al. 2022 Vision RM et al. 2021 Himman RS et al. 2	d exer Total 1 healt 18 52 72 66 172 48 83 24 37 <b>572</b> 293, p	rcise pr Mean -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50 1.60 <0.01 -3.75	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 10.7500 13.9700 12.9100	17 52 70 67 67 57 82 24 51 487	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 13.8700 9.8800		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 0.09 0.24 -0.36	[-1.92, -0 [-0.43] 0 [-0.37] 0 [-1.12] -0 [-0.99] 0 [-0.99] 0 [-0.75] -0 [-0.75] -0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.63] -0.	.47] .34] .28] .42] .41] .10] .13] .66] .67] .08]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.49 5.69 <b>50.49</b>
Test for subgroup differences $z_{0}^{2}$ = 1 <b>sysical function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> Randow H et al. 2020 Raker K et al. 2020 Bennel KL, et al. 2021 Bennel KL, et al. 2021 Bennel KL, et al. 2021 Himman RS et al. 2022 Himman RS et al. 2020 O'Bennel KL, et al. 2021 Himman RS et al. 2020 O'Bennel KL et al. 2020 Himman RS et al. 2020 Himman RS et al. 2020 O'Bennel KL et al. 2020 Himman RS et al. 2020 O'Bennel KL et al. 2020 Himman RS e	d exee Total 1 healt 18 52 72 66 172 48 83 24 37 <b>572</b> 293, p -	rcise pr Mean 4.5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50 1.60 <0.01 -3.75 -3.70	ograms SD 3.1400 10.5300 10.8600 9.3000 10.1000 7.0600 10.7500 13.9700 12.9100	17 52 70 67 67 57 82 24 51 487 208	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.70 -1.70 -2.81 1.00	SD 3.1000 10.6100 10.3500 10.2500 12.2600 12.2600 13.8700 9.8800 11.1300		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 0.09 -0.24 -0.36	[-1.92; -0, [-0.43; 0] [-0.37; 0] [-1.12; -0] [-0.98; -0] [-0.75; -0] [-0.48; 0] [-0.48; 0] [-0.48; 0] [-0.48; 0] [-0.48; -0] [-0.31; 0] [-0.68; -0]	.47] 34] 28] 42] 42] 41] 10] 13] 66] 67] 08] .12] 17]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.49 5.69 5.69 5.69 5.89 5.89
Test for subgroup differences $x_2^2 = 1$ ysical function Telehealth-supporte Study Interventions for clients and AusJorut M et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Bernet KL, et al. 2020 Chirr SA et al. 2020 Himman RS et al. 2020 Li C et al. 2020 Intervention SS et al. 2021 Intervention SS et al. 2021 Intervention y fac. 756, $r = 0.1$ Determogenety $r^2$ ar 756, $r = 0.1$ Det	d exes Total I healt 18 52 72 66 172 48 83 24 37 <b>572</b> 293, p 142 162	rcise pr Mean thcare p -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -0.50 1.60 <0.01 -3.75 -3.70 -7.32	500 moviders 3.1400 10.5300 10.8600 9.3000 10.7500 10.7500 13.9700 12.9100 10.0600 11.0400 3.9200	17 52 70 67 67 57 82 24 51 487 208 94	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 16.3800 13.8700 9.8800 11.1300 5.0500		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.36	[-1.92, -0, [-0.43, 0] [-0.37, 0] [-1.12, 0] [-0.88, -0, [-0.78, -0, [-0.48, 0] [-0.78, -0, [-0.48, 0] [-0.63, -0, [-0.68, 0] [-1.31, -0]	.47] 34] 28] 42] .41] 10] .13] .66] .67] .08] 12] 17] .26]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.69 5.69 5.69 5.69 5.89 5.89 5.89 5.59
Test for subgroup differences $z_{0}^{2}$ = 1 <b>sysical function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> Radsout M et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Bennel KL, et al. 2021 (A) Bennel KL, et al. 2021 (A) Bennel KL, et al. 2021 (A) Bennel KL, et al. 2021 (A) Celler SA et al. 2022 (A) Celler SA et al. 2022 (A) Celler SA et al. 2021 (A) Alaen KO et al. 2021 (A) Arfanc Collinear SS et al. 2021 (A) Arfanc Collinear SS et al. 2021 (A) Arfanc SA et al. 2020 (A) Celler SA et al. 2021 (A) Celler SA et al.	d exer Total 1 healt 18 52 72 666 666 83 24 172 48 83 24 7 <b>572</b> 293, p -	<pre>cise pr Mean -5.11 -0.46 -12.60 -14.40 -10.00 -7.80 -10.90 -0.50 1.60 &lt; 0.01 &lt;-3.75 -3.70 -7.32 0.20</pre>	ograms SD 3.1400 10.5300 10.8600 10.7500 13.9700 12.9100 10.0600 11.0400 3.9200	17 52 70 67 67 57 82 24 51 487 208 94 29 49	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75 -0.60	3.1000 10.6100 10.9900 10.3500 10.2500 11.22600 16.3800 13.8700 9.8800 11.1300 5.0500 20.9000		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.49 -0.49 -0.49 -0.36 -0.09 -0.24 -0.36 -0.09 -0.42 -0.78 -0.04	[-1.92; -0, [-0.43; 0] [-0.37; 0] [-0.99; -0, [-0.88; -0, [-0.75; -0, [-0.48; 0] [-0.63; -0, [-0.63; -0, [-0.63; -0, [-0.31; 0] [-0.63; -0, [-1.31; 0] [-0.36; 0]	.47] 34] 28] 42] 44] 10] 13] .66] .67] .08] .12] 17] 26] .44]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.69 5.69 5.89 5.89 5.89 5.59 5.59
Test for subgroup differences $x_2^2 = 1$ <b>sysical function</b> <b>Telehalth-supporte</b> <b>Study</b> <b>Interventions for clents and</b> <b>AusJour Mr et al.</b> 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Chernel KL, et al. 2021 (II) Bakers K et al. 2020 Cherner SA et al. 2021 (II) LI C et al. 2020 O'Bren KL et al. 2021 Himman RS et al. 2020 O'Bren KL et al. 2021 Himman RS et al. 2021 Himman RS et al. 2021 Himman RS et al. 2021 Himman RS et al. 2021 Baker KD et al. 2022 Baker KD et al. 2023 Baker KD	d exer Total 1 healt 18 52 72 66 172 48 83 32 4 37 <b>572</b> 293, p • 142 162 31 48 107	rcise pr Mean -5.11 -0.46 -12.60 -14.40 -10.90 -0.50 1.60 <0.01 -3.75 -3.70 -7.32 0.20 -9.30	ograms SD 31400 10 5300 10 5300 10 8600 10 1000 7 .0600 11 9700 12 9100 10 0600 11 0400 3 9200 16 6900 9 .6000	17 52 70 67 57 57 82 24 51 487 208 94 29 49 105	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75 -0.60 -4.70	3.1000 10.6100 10.9900 10.3500 10.2500 7.1600 12.2600 16.3800 13.8700 9.8800 11.1300 5.0500		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.42 -0.78 0.04 -0.42	[-1.92; -0 [-0.43] 0 [-0.43] 0 [-0.99; -0 [-0.98; -0 [-0.75] -0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.48] -0 [-0.48]	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] .44] 18]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.69 5.69 5.89 5.89 5.89 5.89 5.89 5.89 5.89
Test for subgroup differences $x_2^2 = 1$ <b>sysial function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> Analorus M et al. 2020 Ealer K et al. 2020 Ealer K et al. 2020 Ealer K et al. 2020 Charr SA et al. 2021 Interventions for clients Aden KO et al. 2018 Aden KO et al. 2018 Aden KO et al. 2018 Aden KO et al. 2021 Ealer SA et al. 2022 Ealer SA et al. 2021 Ealer	d exer Total 1 healt 18 52 72 66 172 48 83 32 4 37 <b>572</b> 293, p • 142 162 31 48 107	rcise pr Mean +	ograms SD 3.1400 10.5300 10.5300 10.1000 9.3000 10.7500 13.9700 12.9100 10.0600 11.0400 3.9200 16.6900 9.6000 12.4400	17 52 70 67 67 57 82 24 51 487 208 94 29 49	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75 -0.60 -4.70 -4.30	SD 3.1000 10.6100 10.9900 10.3500 12.2600 12.2600 13.8700 9.8800 13.8700 9.8800 11.1300 5.0500 20.9000 10.8000 10.8000		-1.20 -0.04 -0.05 -0.77 -0.70 -0.44 0.09 0.24 -0.36 -0.09 -0.42 -0.78 0.04 -0.45	[-1.92; -0. [-0.43; 0] [-0.43; 0] [-0.77; 0] [-0.99; -0] [-0.88; -0] [-0.78; -0] [-0.48; 0] [-0.48; 0] [-0.48; 0] [-0.68; -0] [-1.31; -0] [-0.68; 0] [-1.31; -0] [-0.72; -0] [-0.72; -0] [-0.75; -0]	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] 44] 18] 16]	5.19 5.79 5.79 5.89 5.79 5.69 5.69 5.69 5.89 5.89 5.89 5.89 5.89 5.89 5.89 5.8
Test for subgroup differences $x_2^2 = 1$ ysysial function Telehealth-supporte Study Interventions for clients and AusJorut M et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Demnet K, et al. 2020 Chirr SA et al. 2021 Himman BS et al. 2022 (J) Bernet K, et al. 2022 (J) Bernet K, et al. 2020 (J) Random effects model Adam 50 et al. 2021 Interventery $f = 75\%$ , $f = 0.1$ Demnet K, et al. 2020 Interventery $f = 75\%$ , $f = 0.2$ Demnet K, et al. 2020 Bernet K, et al. 2021 Interventery $f = 75\%$ , $f = 0.2$ Demnet K, et al. 2022 (J) Bernet K, et al. 2022 (J) BernetK, et al. 2022 (J) Bernet K, e	d exee Total f healt 52 72 66 172 48 83 24 43 7 <b>572</b> 293, p • 142 162 31 48 107 91 32 613	rcise pr Mean -5.11 -0.46 -12.60 -14.40 -0.50 1.60 -0.50 1.60 -0.50 1.60 -0.50 -3.75 -3.70 -7.32 0.20 -9.30 -10.10 -3.68	ograms SD 31400 10 5300 10 5300 10 8600 10 1000 7 .0600 11 9700 12 9100 10 0600 11 0400 3 9200 16 6900 9 .6000	17 52 70 67 67 57 82 24 51 487 208 94 29 49 105 92	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75 -0.60 -4.70 -4.30	SD 3.1000 10.6100 10.9900 10.3500 12.2600 12.2600 13.8700 9.8800 11.1300 5.0500 20.9000 10.8000		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.22 -0.78 -0.04 2-0.78 -0.45 -0.45 -0.45 -4.99	[-1.92; -0 [-0.43] 0 [-0.43] 0 [-0.99; -0 [-0.98; -0 [-0.75] -0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.48] 0 [-0.48] -0 [-0.48]	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] .44] 18] 16] 98]	5.19 5.79 5.79 5.79 5.89 5.79 5.79 5.89 5.79 5.49 5.69 5.89 5.89 5.59 5.89 5.59 5.89 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.5
Test for subgroup differences $z_0^2$ = 1 yysical function Telehaath-supporte Study Interventions for clents and Ausdour M et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Bennel K, et al. 2021 Bennel K, et al. 2021 Bennel K, et al. 2021 Himmen RS et al. 2021 Himmen RS et al. 2020 O'Bien Kkil et al. 2021 Himmen RS et al. 2020 O'Bien Kkil et al. 2021 Heterogenety / E - 75%, f = 0. Interventions for clents Alaen KO et al. 2018 Alaen KO et al. 2021 Arlae Colffer S et al. 2022 ( Hetegan RC et al. 2021 Hetegan RC et al. 2021	d exee Total f healt 52 72 66 172 48 83 24 43 7 <b>572</b> 293, p • 142 162 31 48 107 91 32 613	rcise pr Mean -5.11 -0.46 -12.60 -14.40 -0.50 1.60 -0.50 1.60 -0.50 1.60 -0.50 -3.75 -3.70 -7.32 0.20 -9.30 -10.10 -3.68	ograms SD 3.1400 10.5300 10.5300 10.1000 9.3000 10.7500 13.9700 12.9100 10.0600 11.0400 3.9200 16.6900 9.6000 12.4400	17 52 70 67 67 57 82 24 51 487 208 94 29 49 105 29 2 92 32	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75 -0.60 -4.70 -4.30	SD 3.1000 10.6100 10.9900 10.3500 12.2600 12.2600 13.8700 9.8800 13.8700 9.8800 11.1300 5.0500 20.9000 10.8000 10.8000		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.22 -0.78 -0.04 2-0.78 -0.45 -0.45 -0.45 -4.99	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-1.12; -0 [-0.99, -0 [-0.78, -0 [-0.78, -0 [-0.48, 0 [-0.48, 0 [-0.48, 0 [-0.48, 0 [-0.48, -0 [-0.48, -0][-0.48, -0 [-0.48, -0][-0.48	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] .44] 18] 16] 98]	5.19 5.79 5.79 5.79 5.89 5.79 5.79 5.89 5.79 5.49 5.69 5.89 5.89 5.59 5.89 5.59 5.89 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.5
Test for subgroup differences $x_2^2 = 1$ ysysial function Telehaath-supporte Study Interventions for clents and AusJour M via 2020 Baker K et al 2020 Baker K et al 2020 Baker K et al 2020 Ghirr SA et al 2020 Chirr SA et al 2021 Himman RS et al 2021 Himman RS et al 2021 Dennel KL et al 2020 Bernel KL et al 2021 Bernel KL et al 2022 Chirr SA et al 2021 Bernel KL et al 2021 Dennel KL et al 2022 Chirr SA et al 2021 Dennel KL et al 2022 Chirr SA et al 2021 Himman RS et al 2021 Chirr SA et	d exer Total 1 healt 18 52 66 172 66 172 66 172 66 172 24 8 3 24 4 37 572 293, p 142 162 31 48 107 91 32 613 3025, p	rcise pr Mean thcare p -5.11 -0.46 -12.60 -12.60 -7.80 -0.50 1.60 -0.50 1.60 -0.50 -3.70 -3.75 -3.70 -0.20 -0.20 -0.46 -0.50 1.60 -0.50	ograms SD 3.1400 10.5300 10.5300 10.1000 9.3000 10.7500 13.9700 12.9100 10.0600 11.0400 3.9200 16.6900 9.6000 12.4400	17 52 70 67 67 57 82 24 51 487 208 94 29 49 105 29 2 92 32	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -5.80 -1.90 -1.70 -2.81 1.00 -3.75 -0.60 -4.70 -4.30	SD 3.1000 10.6100 10.9900 10.3500 12.2600 12.2600 13.8700 9.8800 13.8700 9.8800 11.1300 5.0500 20.9000 10.8000 10.8000		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.22 -0.78 -0.42 -0.78 -0.45 -0.45 -0.45 -4.99	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-1.12; -0 [-0.99, -0 [-0.78, -0 [-0.78, -0 [-0.48, 0 [-0.48, 0 [-0.48, 0 [-0.48, 0 [-0.48, -0 [-0.48, -0][-0.48, -0 [-0.48, -0][-0.48	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] .44] 18] 16] 98]	5.19 5.79 5.79 5.79 5.89 5.79 5.79 5.89 5.79 5.49 5.69 5.89 5.89 5.59 5.89 5.59 5.89 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.89 5.59 5.5
Test for subgroup differences $x_2^2 = 1$ ysysial function Telehealth-supporte Study Interventions for clients and AusJorut M et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Demnet K, et al. 2020 Chirr SA et al. 2021 Himman BS et al. 2022 (J) Bernet K, et al. 2022 (J) Bernet K, et al. 2020 (J) Random effects model Adam 50 et al. 2021 Interventery $f = 75\%$ , $f = 0.1$ Demnet K, et al. 2020 Interventery $f = 75\%$ , $f = 0.2$ Demnet K, et al. 2020 Bernet K, et al. 2021 Interventery $f = 75\%$ , $f = 0.2$ Demnet K, et al. 2022 (J) Bernet K, et al. 2022 (J) BernetK, et al. 2022 (J) Bernet K, e	d exer Total 1 healt 18 52 72 66 172 48 33 24 37 572 293, p 142 162 31 17 142 162 31 17 91 13 25, p 9 provi	rcise pr Mean -5.11 -0.46 -12.60 -12.60 -10.00 -0.50 1.60 (0.01 -3.75 -3.70 -7.32 0.20 -9.30 -10.10 -3.68 <0.01 ders	ograms         SD           sroviderr         3.1400           10.5300         9.3000           10.7500         10.7500           10.7500         12.9100           10.0600         11.0400           10.0600         12.9100           10.4600         9.6000           12.212         2.420           12.224         9.6000	17 52 70 67 57 82 24 51 487 208 94 29 49 49 105 29 232 609	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -1.90 -1.70 -2.81 1.00 -3.75 -3.75 -4.30 0.14	SD 3.1000 10.9900 10.3500 10.2500 7.1600 12.2600 13.8700 13.8700 9.8800 13.8700 9.8800 20.9000 10.8000 20.9000 10.31300 0.4700		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.49 -0.49 -0.36 -0.09 -0.42 -0.78 0.04 -0.45 -0.45 -0.45 -0.98	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-0.99, 0 [-0.75, -0 [-0.48, 0 [-0.18, 0 [-0.63, -0, [-0.63, -0, [-0.63, 0 [-0.63, 0 [-0.72, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0][-0.75, -0 [-0.75, -0][-0.7	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] .44] 18] 16] 98] 28] 26]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.7
Test for subgroup differences $\chi_2^2$ = 1 yysical function Telehaath-supporte Study Interventions for clents and Ausdour Mr et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Chernel KL, et al. 2021 (I) Bakers K et al. 2020 Cherner SA et al. 2020 Cherner SA et al. 2021 Himman RS et al. 2020 O'Bren KL et al. 2021 Himman RS et al. 2020 O'Bren KL et al. 2021 LI C et al. 2021 Allen KO et al. 2018 Allen KO et al. 2018 Allen KO et al. 2021 Enterventions for clents Allen KO et al. 2021 Random effects anodel Reingement K- et al. 2021 Random effects anodel Reingement K- et al. 2021 Random effects model Heterogenety F = 2024 Random effects model Random effects model Ran	d exer Total 1 healt 18 52 72 66 172 48 83 24 48 83 24 48 83 75 72 293, p 142 213 142 162 31 48 107 91 325, p 9 provi 21	rcise pr Mean thcare ; -5.11 -0.46 -12.60 -12.60 -12.60 -12.60 -12.60 -14.40 -0.50 1.60 -3.70 -3.70 -3.75 -3.70 -3.75 -3.70 -3.75 -3.70 -3.76	ograms SD providern 10 8600 9 3000 10.1000 7 7.0600 10.7500 12.9100 10.0600 11.0400 3.9200 16.6900 12.4400 0.9600 4.0800	17 52 70 67 57 82 24 51 487 208 94 94 29 49 105 92 208 609 21	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -1.90 -3.75 -0.60 -3.75 -0.60 -4.30 0.14 -5.76	SD 3.1000 10.6100 10.9900 10.2500 10.2500 12.2600 16.3800 13.8700 9.8800 11.1300 5.0500 20.9000 10.4700 5.4600		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.49 -0.24 -0.36 -0.09 -0.42 -0.78 -0.04 -0.45 -0.45 -0.45 -0.98	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-0.99, -0 [-0.88, -0 [-0.75, -0 [-0.48, 0 [-0.48, 0 [-0.63, -0. [-0.63, -0. [-0.36, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0]]]]	.47] 34] 28] 42] 41] 10] 13] 66] 67] 08] 12] 17] 26] 18] 18] 18] 18] 18] 18] 26] 98] 26]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.69 5.69 5.89 5.89 5.89 5.89 5.89 5.89 5.89 5.8
Test for subgroup differences $x_{2}^{2} = 1$ <b>sysical function</b> <b>Technath-support</b> <b>study</b> <b>Interventions for clients and</b> <b>Adaption</b> M et al. 2002 Rement RL et al. 2007 (A) Bernet RL et al. 2007 (A)	d exer Total 1 healt 18 healt 18 2 272 66 6 172 48 83 37 572 293, p 172 48 83 37 572 293, p 172 162 31 172 162 31 172 162 31 172 162 61 3 172 172 162 172 172 172 172 172 172 172 172 172 17	rcise pr Mean thcare ; -5.11 -0.46 -12.60 -12.60 -12.60 -12.60 -12.60 -14.40 -0.50 1.60 -3.70 -3.70 -3.75 -3.70 -3.75 -3.70 -3.75 -3.70 -3.76	ograms         SD           sroviderr         3.1400           10.5300         9.3000           10.7500         10.7500           10.7500         12.9100           10.0600         11.0400           10.0600         12.9100           10.4600         9.6000           12.212         2.420           12.224         9.6000	17 52 70 67 57 82 24 51 487 208 94 94 29 49 105 92 208 609 21	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -1.90 -3.75 -0.60 -3.75 -0.60 -4.30 0.14 -5.76	SD 3.1000 10.9900 10.3500 10.2500 7.1600 12.2600 13.8700 13.8700 9.8800 13.8700 9.8800 20.9000 10.8000 20.9000 10.31300 0.4700		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.42 -0.78 -0.45 -0.45 -0.45 -0.45 -0.98 -0.98	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-0.99, 0 [-0.75, -0 [-0.48, 0 [-0.18, 0 [-0.63, -0, [-0.63, -0, [-0.63, 0 [-0.63, 0 [-0.72, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0 [-0.75, -0][-0.75, -0 [-0.75, -0][-0.7	.47] 34] 28] 42] 42] 10] 13] 66] 67] 08] 12] 17] 26] 16] 98] 26] 74] 82]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.7
These for subgroup differences $x_2^2 = 1$ ysical function Telehalth-supporte Study Interventions for clients and Alasforum H et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Baker K et al. 2020 Demnet K, et al. 2020 Himman RS et al. 2020 Chirr SA et al. 2020 Himman RS et al. 2020 ULC et al. 2020 Himman RS et al. 2020 Himman	d exer Total 1 healt 18 healt 18 2 272 66 6 172 48 83 37 572 293, p 172 48 83 37 572 293, p 172 162 31 172 162 31 172 162 31 172 162 61 3 172 172 162 172 172 172 172 172 172 172 172 172 17	rcise pr Mean thcare ; -5.11 -0.46 -12.60 -12.60 -12.60 -12.60 -12.60 -14.40 -0.50 1.60 -3.70 -3.70 -3.75 -3.70 -3.75 -3.70 -3.75 -3.70 -3.76	ograms SD providern 10 8600 9 3000 10.1000 7 7.0600 10.7500 12.9100 10.0600 11.0400 3.9200 16.6900 12.4400 0.9600 4.0800	17 52 70 67 67 57 57 82 24 51 487 208 94 94 94 92 32 609 21 25	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -1.90 -3.75 -0.60 -3.75 -0.60 -4.30 0.14 -5.76	SD 3.1000 10.6100 10.9900 10.2500 10.2500 12.2600 16.3800 13.8700 9.8800 11.1300 5.0500 20.9000 10.4700 5.4600		-1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.44 -0.36 -0.09 -0.42 -0.78 -0.45 -0.45 -0.45 -0.45 -0.98 -0.98	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-0.99, 0 [-0.75, -0 [-0.75, -0 [-0.48, 0 [-0.48, 0 [-0.75, -0 [-0.75, -0][-0.75, -0 [-0.75, -0][-0	.47] 34] 28] 42] 42] 10] 13] 66] 67] 08] 12] 17] 26] 16] 98] 26] 74] 82]	5.19 5.79 5.79 5.79 5.79 5.79 5.79 5.79 5.7
Test for subgroup differences $x_2^2 = 1$ <b>sysial function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> <b>Stady</b> <b>Interventions (a 2020</b> Baker K et al. 2020) Baker K et al. 2020 Charl SA et al. 2021 <b>Interventions for clients</b> Aden KO et al. 2018 Aden KO et al. 2018 Aden KO et al. 2021 Barmal KL, et al. 2020 Charles Charles Charles <b>Interventions for clients</b> <b>Interventions for clients</b> <b>Interven</b>	d exer Total d healt 1 heal	rcise pr Mean thcare ; -5.11 -0.46 -12.60 -12.60 -12.60 -12.60 -12.60 -14.40 -0.50 1.60 -3.70 -3.70 -3.75 -3.70 -3.75 -3.70 -3.75 -3.70 -3.76	ograms SD providern 10 8600 9 3000 10.1000 7 7.0600 10.7500 12.9100 10.0600 11.0400 3.9200 16.6900 12.4400 0.9600 4.0800	17 52 70 67 57 82 24 51 487 208 94 92 92 32 609 21 25 46	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -1.90 -3.75 -0.60 -3.75 -0.60 -4.30 0.14 -5.76	SD 3.1000 10.6100 10.9900 10.2500 10.2500 12.2600 16.3800 13.8700 9.8800 11.1300 5.0500 20.9000 10.4700 5.4600		+1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.49 -0.49 -0.24 -0.36 -0.78 -0.78 -0.78 -0.78 -0.78 -0.78 -0.74 -0.45 -0.45 -0.45 -0.58 0.20 0.21 0.20 0.20	[-1.92; -0, [-0.37] 0, [-0.37] 0, [-0.37] 0, [-0.99] -0, [-0.88] -0, [-0.78] 0, [-0.48] 0, [-0.47] 0, [-0.75] 0,\\[-0.75]	.47] 34] 28] 42] 41] 10] 13] 66] 667] 08] 12] 17] 26] .44] 18] 16] 98] 26] .74] .82] .61]	5.11 5.79 5.79 5.79 5.79 5.69 5.89 5.89 5.89 5.89 5.89 5.89 5.89 5.8
Test for subgroup differences $\chi_2^2$ = 1 yysical function Telehaath-supporte Study Interventions for clents and AusJour M vi at 0.002 Baker K et al 2020 Baker K et al 2020 Baker K et al 2020 Baker K et al 2020 Chernel Ki, et al 2020 Baker KO et al 2018 Alaen KO et al 2018 Alaen KO et al 2021 Bornel Ki, et al 2020 Bornel Ki, et al 2020 Chernel Ki, et al 2020 Bornel Ki, et al 2020 B	d exee Total 1 healt 18 52 72 66 172 48 83 24 37 72 66 172 48 83 24 37 72 672 293, p - 142 162 31 48 107 19 10 20 10 10 10 10 10 10 10 10 10 1	rcise pr Mean thcare p -5.11 -0.46 -12.60 -14.40 -0.50 1.60 -0.50 1.60 -3.75 -7.32 0.20 -9.30 -10.10 -3.68 <0.01 -0.58 -0.51 -0.58 -0.51 -0.50 -0.50 -0.50 -0.50 -0.50 -0.51 -0.50 -	ograms SD providern 10 8600 9 3000 10.1000 7 7.0600 10.7500 12.9100 10.0600 11.0400 3.9200 16.6900 12.4400 0.9600 4.0800	17 52 70 67 67 57 57 82 24 51 487 208 94 94 94 92 32 609 21 25	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -1.90 -3.75 -0.60 -3.75 -0.60 -4.30 0.14 -5.76	SD 3.1000 10.6100 10.9900 10.2500 10.2500 12.2600 16.3800 13.8700 9.8800 11.1300 5.0500 20.9000 10.4700 5.4600		+1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.49 -0.49 -0.24 -0.36 -0.78 -0.78 -0.78 -0.78 -0.78 -0.78 -0.74 -0.45 -0.45 -0.45 -0.58 0.20 0.21 0.20 0.20	[-1.92, -0 [-0.43, 0 [-0.37, 0 [-0.99, 0 [-0.75, -0 [-0.75, -0 [-0.48, 0 [-0.48, 0 [-0.75, -0 [-0.75, -0][-0.75, -0 [-0.75, -0][-0	.47] 34] 28] 42] 41] 10] 13] 66] 667] 08] 12] 17] 26] .44] 18] 16] 98] 26] .74] .82] .61]	Weigh 5.19 5.79 5.89 5.59 5.89 5.59
Test for subgroup differences $x_2^2 = 1$ <b>sysial function</b> <b>Telehealth-supporte</b> <b>Study</b> <b>Interventions for clients and</b> <b>Stady</b> <b>Interventions (a 2020</b> Baker K et al. 2020) Baker K et al. 2020 Charl SA et al. 2021 <b>Interventions for clients</b> Aden KO et al. 2018 Aden KO et al. 2018 Aden KO et al. 2021 Barmal KL, et al. 2020 Charles Charles Charles <b>Interventions for clients</b> <b>Interventions for clients</b> <b>Interven</b>	d exer Total d healt 1 heal	rcise pr Mean thcare ; -11, -0, 46 -12, 60 -12, 60 -14, 40 -12, 60 -14, 40 -0, 50 -1, 60 -0, 50 -1, 60 -3, 70 -3, 68 -5, 10 -10, 86 -10, 86 -10, 86 -10, 80 -10, 80 -1	ograms SD providern 10 8600 9 3000 10.1000 7 7.0600 10.7500 12.9100 10.0600 11.0400 3.9200 16.6900 12.4400 0.9600 4.0800	17 52 70 67 57 82 24 51 487 208 94 92 92 32 609 21 25 46	Mean -1.29 -0.01 -12.10 -6.80 -2.90 -4.30 -1.90 -3.75 -0.60 -3.75 -0.60 -4.30 0.14 -5.76	<b>SD</b> 3,1000 10,5100 10,9500 10,3500 10,3500 10,3500 11,38700 9,88000 11,38700 9,88000 10,8000 10,4700 5,4600 13,7900		+1.20 -0.04 -0.05 -0.77 -0.70 -0.49 -0.49 -0.49 -0.24 -0.36 -0.78 -0.78 -0.78 -0.78 -0.78 -0.78 -0.74 -0.45 -0.45 -0.45 -0.58 0.20 0.21 0.20 0.20	[-1.92; -0, [-0.37] 0, [-0.37] 0, [-0.37] 0, [-0.99] -0, [-0.88] -0, [-0.78] 0, [-0.48] 0, [-0.47] 0, [-0.75] 0,\\[-0.75]	.47] 34] 28] 42] 41] 10] 13] 66] 667] 08] 12] 17] 26] .44] 18] 16] 98] 26] .74] .82] .61]	5.11 5.79 5.79 5.79 5.79 5.69 5.89 5.89 5.89 5.89 5.89 5.89 5.89 5.8

### Figure 3

See image above for figure legend.

Figure 4: Subgroup analysis of pain and physical function based on the type of digital


#### technology Pain

			rogram-			Control	Standardised Mean				
Telehealth-support Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD		6%-CI	Weight
Mobile app							1				
Alasfour M et al. 2022 Arfaei Chitkar SS et al. 2021	18	-2.22	1.8300	29	-0.82	2.1300		-0.69	1.1.38	-0.01	4.4%
Gohir SA et al. 2021	48	-1.80		82	-0.30	1.9500		-0.77	-1.14	-0.401	5.4%
Thiengwittayaporn S et al. 2021	1 42	1.30	7.0100	40	1.40	5.9000	+	-0.02	1-0.45	0.42]	5.3%
Random effects model Heterogeneity: $l^2 = 68\%$ , $\tau^2 = 0.122$	139 28, p = 0	02		168				-0.59	[-1.01;	-0.16]	20.1%
Internet											
Allen KD et al. 2018			3.2500	208 67		3.2300	1	-0.13			5.8%
Aten KD et al. 2018 Bennell KL et al. 2017 (B) Bennell KL et al. 2022 (B)	107		2 3000	105		2.4000	1	-0.48	1-0.83	-0.14]	5.7%
	315		2.0000	380		2.4050	•	-0.25	[-0.43:	-0.071	17.0%
Heterogeneity: $l^2 = 3116$ , $t^2 = 0.003$	76, p = 0	23									
Mixed type Allen KD et al. 2021	163	-1.00	3 2600	94	0.40	3.4600	-	-0.42	1-0.68	-0.161	5.7%
Bennell KL et al. 2022 (A)	172		1.6800	67	-1.70	1.8400	+	-0.52	1-0.81	-0.23]	5.6%
Hinman RS et al. 2020	83	-2.50	1.8700	82	-1.80	1.9500	+	-0.36	[-0.67]	-0.06]	5.6%
Hsu Yi et al. 2021 Li LC et al. 2020	21	-1.91	1.7900	21 24	-2.15	1.9900	II.	0.12	1-0.48	0.73]	4.7%
Noligan RK et al. 2021	91	-2.80		92	-1.20	2.1000	+		[-1.09]		5.6%
O'Brien KM et al. 2018	59	-0.30	2.2400	60	-0.90	2.5000	+	0.25	[-0.11]	0.61]	5.5%
Random effects model Heterogeneity: 1 <sup>2</sup> = 75%, 1 <sup>2</sup> = 0.102	613 27. p < 0	.01		440			0	-0.29	[-0.57;	-0.01]	37.5%
Telephone											
Baker K et al. 2020	52	-0.80	3.6400	52	-0.62	3.6800	it i	-0.05	[-0.43	0.34]	5.4%
Bennell KL et al. 2017 (A) Odole AC et al. 2013	72	-2.50	1.9300	70	-2.00	2.0200	Ť.	-0.25	[-0.58 [-0.28	0.08]	5.5%
Random effects model	149	-32.28	10.0000	147	-31.00	10.3900	4	-0.08	[-0.28	0.181	4.9%
Heterogeneity: $l^2 = 24\%$ , $\tau^2 = 0.005$		27									
SMS Bennell KL et al. 2020	40	0.60	2.1500	49	0.20	2.3500		0.19	1-0.22	0.571	5.4%
Rafig MT et al. 2021	32	-2.75	0.8700	32	-0.28			-3.02	1-3.75	-2.29]	4.3%
Random effects model Heterogeneity: $l^2 = 98\%$ , $\tau^2 = 5.021$	80	01		81				-1.41	[-4.54;	1.73]	9.6%
				1216							103.0%
Random effects model Heterogeneity: $l^2 = 83%$ , $t^2 = 0.345$ Test for averall effect: $z = -2.70$ (p Test for subgroup differences: $\chi^2_4$ =	1296	04		1216				-0.39	[-0.67;	-0.11]	100.0%
Test for overall effect z = -2.70 (p	<0.01)						4 2 0 2 4	4			
ical function											
Telehealth-supporte	ed exer Total	cise pr Mean	ograms SD	Total	Mean	Control	Standardised Mean Difference	SMC	5	95%-	CI Weig
Telehealth-supports Study	ed exer Total	cise pr Mean	rograms SD	Total	Mean			SMC	5	95%-	CI Welg
Telehealth-supporte Study Mobile app Alastour M et al. 2022	Total	Mean -5 11	SD 3.1400	17	Mean	SD 3.1000		-1.2	10	2 -0.4	71 51
Telehealth-supports Study Mobile app Alasfour M et al. 2022 Arfrei Chikar SS et al. 2021	18 31	-5.11 -7.32	3.1400 3.9200	17	-1.29 -3.75	<b>SD</b> 3.1000 5.0500		-1.2	10	2 -0.4	71 51
Telehealth-supports Study Mobile app Alasfour M et al. 2022 Arfaei Chilkar SS et al. 2021 Gohir SA et al. 2021	18 31 48	Mean -5 11	SD 3.1400	17 29 57	Mean	SD 3.1000		-1.20 -0.70 -0.49	) [-1.9 3 [-1.3 9 [-0.8	2, -0.4	7] 5.1 6] 5.5 0] 5.7
Telehealth-supports Study Mobile app Alasfour M et al. 2022 Arfrei Chikar SS et al. 2021	18 31 48 97	-5.11 -7.32 -7.80	3.1400 3.9200	17	-1.29 -3.75	<b>SD</b> 3.1000 5.0500		-1.20 -0.70 -0.49	) [-1.9 3 [-1.3 9 [-0.8	2, -0.4	7] 5.1 6] 5.5 0] 5.7
Telehealth-supports Study Mobile app Alesiour M et al. 2022 Arfuei Chikar SS et al. 2021 Gohir SA et al. 2021 Random effects model Heterspereky. /* a 34%, z <sup>2</sup> = 0.0 Internet	18 31 48 97 349, p =	-5.11 -7.32 -7.80	SD 3.1400 3.9200 7.0600	17 29 57 103	-1.29 -3.75 -4.30	3.1000 5.0500 7.1600		-1.21 -0.71 -0.49 -0.73	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1	2; -0.4 1; -0.2 8; -0.1 0; -0.3	7] 5.1 8] 5.5 0] 5.7 6] 16.3
Telehealth-supports Study Mobile app Alastiour M et al. 2022 Arlori Chittar SS et al. 2021 Gohir SA et al. 2021 Random effects model Heterogenety. // = 34%, c <sup>2</sup> = 0.0 Internet Aden KD et al. 2018	18 31 48 97 349, p = 142	Mean -5.11 -7.32 -7.80 0.22 -3.75	SD 3.1400 3.9200 7.0600	17 29 57 103 208	Mean -1.29 -3.75 -4.30	SD 3.1000 5.0500 7.1600 9.8800		-1.21 -0.71 -0.45 -0.73	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1	2; -0.4 1; -0.2 8; -0.1 0; -0.3	7] 5.1 6] 5.5 0] 5.7 6] 16.3
Telehealth-supports Study Mobile app Arafotr Altar 4 el. 2022 Arfaret Calitar SS et al. 2021 Gonir SA et al. 2021 Random effects model Hetersgenety, r <sup>2</sup> = 34%, t <sup>2</sup> = 0.0 Internet Allen KD et al. 2011 (B Bennet KL et al. 2017 (B) Bennet KL et al. 2017 (B)	18 31 48 97 349, p = 142 66	-5.11 -7.32 -7.80 0.22 -3.75 14.40	SD 3.1400 3.9200 7.0600 10.0800 9.3000	17 29 57 103 208 67	Mean -1.29 -3.75 -4.30 -2.81 -6.80	\$D 3.1000 5.0500 7.1600 9.8800 10.3500		-1.21 -0.71 -0.45 -0.73	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1	2; -0.4 1; -0.2 8; -0.1 0; -0.3	7] 5.1 6] 5.5 0] 5.7 6] 16.3
Telehealth-supports Study Mobile app Alestiour M et al. 2022 Artieri Chittee SS et al. 2021 Gohir SA et al. 2021 Random effects model Heterogenety. // = 34%, c <sup>2</sup> = 0.0 Internet Adem KD et al. 2018 Bornof KL et al. 2022 (B) Bornof KL et al. 2022 (B) Bornof KL et al. 2022 (B)	18 31 48 97 349, p = 142 66 107	-5.11 -7.32 -7.80 0.22 -3.75 14.40	SD 3.1400 3.9200 7.0600	17 29 57 103 208 67 105	Mean -1.29 -3.75 -4.30 -2.81 -6.80	SD 3.1000 5.0500 7.1600 9.8800		-1 20 -0.70 -0.49 -0.73 -0.08 -0.73 -0.08	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1 9 [-0.3 7 [-1.1 5 [-0.7	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.1	7] 5 1 6] 5 5 0] 5 7 <b>6] 16.3</b> 2] 5 8 2] 5 8 2] 5 8
Telehealth-supports Study Mobile app Arafotr Altar 4 el. 2022 Arfaret Calitar SS et al. 2021 Gonir SA et al. 2021 Random effects model Hetersgenety, r <sup>2</sup> = 34%, t <sup>2</sup> = 0.0 Internet Allen KD et al. 2011 (B Bennet KL et al. 2017 (B) Bennet KL et al. 2017 (B)	18 31 48 97 349, p = 142 66 107 315	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30	SD 3.1400 3.9200 7.0600 10.0800 9.3000	17 29 57 103 208 67	Mean -1.29 -3.75 -4.30 -2.81 -6.80	\$D 3.1000 5.0500 7.1600 9.8800 10.3500		-1 20 -0.70 -0.49 -0.73 -0.08 -0.73 -0.08	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.1	7] 5 1 6] 5 5 0] 5 7 <b>6] 16.3</b> 2] 5 8 2] 5 8 2] 5 8
Telehealth-supports Study Model app Aschart M et al. 2022 Andra Chikara Statistica Golar SA et al. 2021 Golar SA et al. 2021 Golar SA et al. 2021 Random effects model Hetersoperety. / F = 24%, f = 0.0 Mandom effect model Hetersoperety. / F = 25%, f = 0.0 Mixed type	18 31 48 97 349, p = 142 66 107 315 1020, p <	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01	SD 3 1400 3 9200 7 0600 9 0000 9 3000 9 6000	17 29 57 103 208 67 105 380	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70	\$D 3 1000 5.0500 7.1600 9.8800 10.3500 10.8000		-1 21 -0.77 -0.45 -0.77 -0.05 -0.77 -0.45 -0.45	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1 9 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8	2; -0.4 1; -0.2 8; -0.1 0; -0.3 1; 0.1 2; -0.4 2; -0.4 0; -0.0	7] 5 1 8] 5 5 0] 5 7 6] 16.3 2] 5 8 2] 5 8 2] 5 8 4] 17.3
Telehealth-supports Study Mobile app Aschart M at all 2022 Aschart M at all 2021 Cohr Sh At all 2021 Random efficter model Interresponder; // = 34%, r <sup>2</sup> = 0.0 Internet Random efficter autor (1) Bennot RL, et al. 2022 (1) Bennot RL, et al. 2022 (2) Random efficter model Heterspenety; // = 45%, r <sup>2</sup> = 0.0 Random efficter model Heterspenety; // = 45%, r <sup>2</sup> = 0.0 Romol RL et al. 2022 (1) Romol RL et al. 2022 (1)	Total 18 31 48 97 349, p = 142 66 107 315 920, p < 162	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70	SD 3.1400 3.9200 7.0600 10.0800 9.3000	17 29 57 103 208 67 105	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00	\$D 3.1000 5.0500 7.1600 9.8800 10.3500		-1.2( -0.7) -0.4( -0.7) -0.4( -0.4( -0.4( -0.4( -0.4( -0.4(	) [-1.9 3 [-1.3 9 [-0.8 5 [-1.1 9 [-0.3 7 [-1.1 5 [-0.7 8 [-0.8 2 [-0.8	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.4 2, -0.1 0; -0.0 8, -0.1 9, -0.4	7] 5.1 6] 5.5 0] 5.7 6] 16.3 2] 5.8 2] 5.7 8] 5.8 4] 17.3 7] 5.8
Telehealth-supports Study Model app Assistant M et al. 2002 Andra Chikara Statut Andra Chikara Statut Andra Chikara Statut Andra Chikara Statut Andra Chikara Statut Andra Chikara Statut Andra Chikara Statut Bennel KL et al. 2022 (B) Bennel KL et al. 2022 (B) Bennel KL et al. 2022 (B) Bennel KL et al. 2022 (B) March Statut March Statut Andra Andra Statut Andra Statut Andra Statut Andra Statut Andra Andra Statut Andra Andra Andra Statut Andra Andra Andre Andra Andra Andr	Total 18 31 48 97 349, p = 142 66 107 315 120, p < 162 172 83	Mean -5 11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90	SD 3.1400 3.9200 7.0600 10.0600 9.6000 11.0400 10.1000 10.7500	17 29 57 103 208 67 105 389 94 67 82	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.80	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.8000 11.1300 10.2500 12.2600		-1.2( -0.7) -0.45 -0.7) -0.45 -0.45 -0.44 -0.44 -0.44 -0.45 -0.45 -0.45	) [-1.9 3 [-1.3 9 [-0.8 8 [-1.1 9 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8 2 [-0.8 9 [-0.9 4 [-0.7	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.1 0; -0.0 8, -0.1 9, -0.4 5, -0.1	7] 5.1 6] 5.5 0] 5.7 6] 16.3 2] 5.8 2] 5.7 8] 5.8 4] 17.3 7] 5.8 3] 5.7 5.8 4] 17.3 7] 5.8 3] 5.7 5.7 5.8 3] 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7
Telehealth-supports Study Mobile sep Alestour M et al. 2022 Gohr SA et al. 2021 Gohr SA et al. 2021 Unterstand Unterstand Hentensgenetic, F al. 346, s <sup>-1</sup> al. Bennot R, et al. 2021 Bennot R, et al. 2021 (B Bennot R, et al. 2020) Mixed type Alen KD et al. 2021 Bennot R, et al. 2020 (H) Hentensymetric F al. 2021 (H) Bennot R, et al. 2020 (H)	Total 18 31 48 97 349, p = 142 66 107 315 9(20, p < 162 172 83 21	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90 -5.10	SD 3.1400 3.9200 7.0600 10.0800 9.3000 9.6000 11.0400 10.1000 10.7500 4.0600	17 29 57 103 208 67 105 389 94 67 82 21	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -5.80 -5.76	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.8000 11.1300 10.2500 12.2000 5.4600		-1 21 -0.77 -0.44 -0.75 -0.45 -0.75 -0.44 -0.44 -0.44 -0.44	2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 3 [-0.4 3 [-0.4 4 [-0.8 2 [-0.8 4 [-0.8 5 [-0.4 5 [-0.4 5 [-0.4 5 [-0.4 5 [-0.4 5 [-0.8 5 [-0.8] 5 [-0.8 5 [-0.8] 5 [-0	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.4 0; -0.0 8, -0.1 9; -0.4 7; 0.7	7] 5 1 8] 5.5 0] 5.7 6] 16.3 2] 5.8 2] 5.7 8] 5.8 4] 17.3 7] 5.8 3] 5.7 4] 5.4 4] 5.4 4] 5.4 4] 5.4 4] 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5
Telehealth-supports Study Mobile app Alesfour M et al. 2022 Annot Charles 28 et al. 2021 Random effects model Internsperech, 7° a 295, 1° a 00 Metrosperech, 7° a 295, 1° a 00 Metrosperech, 7° a 2022 (b) Hetersperech, 7° a 2023	Total 18 31 48 97 349, p = 142 66 107 315 102, p = 162 172 83 24	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 -5.10 -0.50	SD 3.1400 3.9200 7.0600 10.0800 9.3000 9.6000 11.0400 10.1000 10.700 4.0600 13.9700	17 29 57 103 208 67 105 389 94 67 821 24	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.76 -1.90	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.8000 11.1300 10.2500 12.2000 5.4600 16.3800		-1 27 -0.44 -0.75 -0.65 -0.77 -0.45 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.71 -0.44 -0.71 -0.44 -0.71 -0.44 -0.71 -0.44 -0.71 -0.44 -0.75	2 (-0.6 2 (-0.6 2 (-0.6 2 (-0.6 0 (-0.9 4 (-0.7 4 (-0.7 5 (-0.7 5 (-0.7 6 (-0.7 6 (-0.7 6 (-0.7 6 (-0.7 6 (-0.7 6 (-0.7 7 (-0.7) 7 (	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.4 2, -0.1 0; -0.0 8, -0.1 9; -0.4 5, -0.1 7; 0.6	7] 51 6] 55 0] 57 6] 16.3 2] 58 2] 5.7 8] 5.8 4] 17.3 7] 58 1] 58 3] 5.7 4] 5.4 6] 5.4 6] 5.4 6] 5.4 6] 5.4 6] 5.5 7] 5.8 7]
Totehnalth-supports           Stady         Reclars of Net all 2002           Alexing the field 2002         Reclars of Net all 2002           Alexing the field 2003         Reclars of Net all 2003           Marching the field 2003         Reclars of Alexing 2004           Marching the field 2003         Reclars of Alexing 2004           Marching the field 2003         Reclarge 2004           Marching the field 2003         Reclarge 2004           Marching the field 2004         Reclarge 2004           Marching the field 2004         Reclarge 2004           Marching the field 2004         Reclarge 2004           Marching and 2004         Reclarge 2004	18 31 48 97 349, p = 142 66 107 315 120, p < 162 172 83 21 24 91	-5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90 -5.10 10.10	SD 3 1400 3 9200 7 0600 10 0800 9 3000 9 6000 11 0400 10 1000 10 1000 10 0500 4 0600 13 9700 12 4400	17 29 57 103 208 67 105 389 94 67 82 21 292	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.80 -5.76 -1.90 -4.30	\$D 3 1000 5.0500 7.1600 9.8800 10.3500 10.3500 10.8000 11.1300 10.2500 12.2000 5.4600 16.3800 13.1300		-1 21 -0.77 -0.49 -0.75 -0.49 -0.42 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.74 -0.74 -0.75 -0.45 -0.77 -0.77	2 (-0.6 2 (-0.6 2 (-0.6 2 (-0.6 2 (-0.6 0 (-0.9 4 (-0.7 3 (-0.7 3 (-0.7 4 (-0.7 5 (-0.7 5 (-0.7 5 (-0.7 5 (-0.7 5 (-0.7 5 (-0.7) 5	2, -0.4 1, -0.2 8, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.1 0; -0.0 8, -0.1 9; -0.4 5, -0.1 7, 0.7 8, -0.1	7] 5.1 6] 5.5 0] 5.7 6] 16.3 2] 5.8 2] 5.8 4] 17.3 7] 5.8 3] 5.7 4] 5.4 6] 5.4 6] 5.4
Tetehnalth-support           Staty         Modes of all 2022           Adolstor Mark Science Caller Sc	18         31           48         97           349, p =         66           107         315           162         172           83         21           24         91           37         3690	Mean -5.11 -7.32 -7.80 0.22 -3.75 -3.75 -3.70 0.01 -3.70 10.00 -0.510 -0.510 1.60 1.60	SD 3.1400 3.9200 7.0600 10.0800 9.3000 9.6000 11.0400 10.1000 10.700 4.0600 13.9700	17 29 57 103 208 67 105 389 94 67 821 24	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.80 -5.76 -1.90 -4.30	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.8000 11.1300 10.2500 12.2000 5.4600 16.3800		-1.22 -0.77 -0.44 -0.77 -0.45 -0.45 -0.45 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.77	) [-1.9 3 [-1.3 3 [-1.3 9 [-0.3 7 [-1.1 7 [-1.1] [-1.1 7 [-1.1]	2, -0.4 1, -0.2 3, -0.1 0, -0.3 1, 0.1 2, -0.4 2, -0.1 0, -0.0 8, -0.1 9, -0.4 8, -0.1 9, -0.4 8, -0.1 9, -0.4 8, -0.1 9, -0.5 8, -0.1 9, -0.5 1, -	7] 5 1 6] 5 5 0] 5 7 6] 16.3 2] 5 8 2] 5 8 2] 5 8 2] 5 8 4] 17.3 7] 5 8 1] 5 8 3] 5 7 4] 5 8 3] 5 7 4] 5 8 6] 5 8 7] 5 8 7] 5 8 6] 5 8 7] 5
Tothnesh-support           Mode app           Andreas Orden applications           Andreas Orden applications           Andreas Orden applications           Marchan Orden applications	18         31           48         97           349, p =         66           107         315           162         172           83         21           24         91           37         3690	Mean -5.11 -7.32 -7.80 0.22 -3.75 -3.75 -3.70 0.01 -3.70 10.00 -0.510 -0.510 1.60	SD 3 1400 3 9200 7 0600 10 0800 9 3000 9 6000 11 0400 10 1000 10 1000 10 0500 4 0600 13 9700 12 4400	17 29 57 103 208 67 105 389 94 67 82 21 24 951	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.80 -5.76 -1.90 -4.30	\$D 3 1000 5.0500 7.1600 9.8800 10.3500 10.3500 10.8000 11.1300 10.2500 12.2000 5.4600 16.3800 13.1300		-1.22 -0.77 -0.44 -0.77 -0.45 -0.45 -0.45 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.77	) [-1.9 3 [-1.3 3 [-1.3 9 [-0.3 7 [-1.1 7 [-1.1] [-1.1 7 [-1.1] [	2, -0.4 1, -0.2 3, -0.1 0; -0.3 1, 0.1 2, -0.4 2, -0.1 0; -0.0 8, -0.1 9, -0.4 8, -0.5 9, -0.4 9, -	7] 5 1 6] 5 5 0] 5 7 6] 16.3 2] 5 8 2] 5 8 2] 5 8 2] 5 8 4] 17.3 7] 5 8 1] 5 8 3] 5 7 4] 5 8 3] 5 7 4] 5 8 6] 5 8 7] 5 8 7] 5 8 6] 5 8 7] 5
To the health - support of the second secon	18         31           31         49, p           142         66           107         315           102, p         102           112         24           91         21           24         91           36         315           102         107           315         315           102         107           315         315           102         107           315         315           102         107           315         315           102         107           315         315           102         107           315         315           102         107           315         321           24         91           590         839, p	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90 -5.10 -0.50 1.60 0.01	SD 3.1400 3.9200 7.0600 7.0600 9.0000 9.6000 11.0400 10.1000 10.7500 4.0600 13.9700 12.9100	17 29 57 103 208 67 105 380 94 67 82 21 24 92 51 431	Mean -1.29 -2.81 -2.81 -2.81 -2.81 -2.81 -2.90 -5.76 -1.90 -1.70	\$D \$.1000 \$.0500 7.1600 9.8800 10.3500 10.3500 10.8000 11.1300 10.2500 12.2000 15.4600 16.3800 13.8700		-1 22 -0.71 -0.44 -0.77 -0.47 -0.77 -0.44 -0.77 -0.44 -0.41 -0.42 -0.42 -0.42 -0.42 -0.42 -0.42 -0.42 -0.42 -0.22	) [-1.9 [-0.3 [-0.3 [-0.3 [-0.3 [-0.3 [-0.4] [-0.4 [-0.4] [-0.4 [-0.4]	2: -0.4 1: -0.2 8: -0.1 0: -0.3 1: -0.4 2: -0.1 0: -0.0 8: -0.1 9: -0.4 8: -0.1 7: -0.7 8: -0.1 7: -0.7 8: -0.1 7: -0.4 4: -0.0	7] 5.1 6] 5.5 0] 5.7 6] 16.3 2] 5.8 2] 5.7 8] 5.8 4] 17.3 7] 5.8 3] 5.7 4] 5.4 6] 5.4 6] 5.4 6] 5.6 7] 5.6 2] 39.4
Tothnabh-support           Moles age         Antes Orac           Antes Orac         Antes Orac           Man KD 44         2010           Bound RL (et al. 2021)         Bound RL (et al. 2021)           Bound RL (et al. 2020)         Huser Orac           Huser Orac         2010           Huser Orac         2010           Bound RL (et al. 2020)         Huser Orac           Man KD 44         2010           Bound RL (et al. 2021)         Bound RL (et al. 2021)           Bound RL (et al. 2020)         HL (et al. 2020)           Bound RL (et al. 2020)         HL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)	18         31           3149, p =         142           106         107           316         20, p            102         172           112         21           24         99           91         37           590         8639, p            52         72	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.00 10.00 10.00 0.510 -0.510 1.60 0.01 -0.466 12.60	SD 3.1400 3.9200 7.0600 10.0600 9.0000 11.0400 10.1000 10.7500 4.0600 13.9700 12.9100 10.5300 10.6500	17 29 57 103 208 67 105 389 94 67 82 21 24 431 431 52 70	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.76 -1.90 -5.76 -1.90 -1.70 -0.01 -1.210	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.3500 10.8000 11.1300 10.2200 12.2000 5.4600 16.3800 13.3700 10.6100 10.6100 10.9900		-1.22 -0.77 -0.44 -0.77 -0.44 -0.77 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.45 -0.44 -0.22 -0.23 -0.24 -0.23	) [-1.9 3 [-1.3 9 [-0.8 9 [-0.8 9 [-0.3 9 [-0.3] 9 [	2: -0.4 1: -0.2 3: -0.5 1: -0.3 1: -0.4 3: -0.5 3: -0.6 5: -0.1 5: -0.6 5:	7] 51 6] 55 7] 16.3 7] 5.8 7] 5.8
To the half h-support of the second	Total           18           31           48           97           349, p =           142           66           107           315           100, p            102           102           102           103           21           23           21           24           91           32           112           24           91           3630, p            522           25	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.00 10.00 10.00 0.510 -0.510 1.60 0.01 -0.466 12.60	SD 3.1400 3.9200 7.0600 10.0600 9.6000 9.6000 11.0400 10.7500 4.0600 12.9100 12.9100 10.5300	17 29 57 103 208 67 105 380 94 67 82 21 24 92 51 431 52 70 25	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.76 -1.90 -5.76 -1.90 -1.70 -0.01 -1.210	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.3500 10.8000 11.1300 10.2500 12.2600 5.4600 13.1300 13.8700 10.6100		-1 22 -0.7 -0.7 -0.7 -0.7 -0.7 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4	) [-1.9 3 [-1.3 9 [-0.8 5 [-1.1] 9 [-0.3 5 [-0.7 2 [-0.8 2 [-0.6 0 [-0.7 3 [-0.4 5 [-0.7 5 [-0.3 5 [-0.3] 5 [-0.3] 5	2 -0.4 1 -0.2 8 -0.1 0; -0.3 1; 0.1 2; -0.4 2; -0.1 0; -0.0 8, -0.1 9; -0.4 5; -0.7 8, 0.6 5; -0.7 8, 0.6 4; -0.0 3; 0.3 0; 0.8 1; 0.3 0; 0.0 1; 0.3 1; 0,	7] 5 1 6] 557 6] 16.3 7] 58 6] 16.3 7] 58 6] 7.5 7] 58 6] 7.5 7] 58 7] 58 7
Tothnabh-support           Moles age         Antes Orac           Antes Orac         Antes Orac           Man KD 44         2010           Bound RL (et al. 2021)         Bound RL (et al. 2021)           Bound RL (et al. 2020)         Huser Orac           Huser Orac         2010           Huser Orac         2010           Bound RL (et al. 2020)         Huser Orac           Man KD 44         2010           Bound RL (et al. 2021)         Bound RL (et al. 2021)           Bound RL (et al. 2020)         HL (et al. 2020)           Bound RL (et al. 2020)         HL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)           Bound RL (et al. 2020)         Bound RL (et al. 2020)	18         31           48         97           97         349, p =           142         66           107         315           321         24           24         91           37         590           820, p =         52           72         24           142         91           37         590           52         72           25         149	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.00 10.00 10.00 0.510 -0.510 1.60 0.01 -0.466 12.60	SD 3.1400 3.9200 7.0600 10.0600 9.0000 11.0400 10.1000 10.7500 4.0600 13.9700 12.9100 10.5300 10.6500	17 29 57 103 208 67 105 389 94 67 82 21 24 431 431 52 70	Mean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 1.00 -2.90 -5.76 -1.90 -5.76 -1.90 -1.70 -0.01 -1.210	\$D 3.1000 5.0500 7.1600 9.8800 10.3500 10.3500 10.8000 11.1300 10.2200 12.2000 5.4600 16.3800 13.3700 10.6100 10.6100 10.9900		-1 22 -0.7 -0.7 -0.7 -0.7 -0.7 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4	) [-1.9 3 [-1.3 9 [-0.8 9 [-0.8 9 [-0.3 9 [-0.3] 9 [	2 -0.4 1 -0.2 8 -0.1 0; -0.3 1; 0.1 2; -0.4 2; -0.1 0; -0.0 8, -0.1 9; -0.4 5; -0.7 8, 0.6 5; -0.7 8, 0.6 4; -0.0 3; 0.3 0; 0.8 1; 0.3 0; 0.0 1; 0.3 1; 0,	7] 5 1 6] 557 6] 16.3 7] 58 6] 16.3 7] 58 6] 7.5 7] 58 6] 7.5 7] 58 7] 58 7
Total hash-support           Description         2000           Arbite Cheller Stort and 2010         Arbite Cheller Stort and 2010           Arbite Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010           March Cheller Stort and 2010         Arbite Cheller Stort and 2010	Total         18           18         31           48         97           949         97           142         66           107         315           201         102           112         83           211         24           91         37           590         609, p            52         72           255         149           = 0.62         0.62	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.90 -0.50 10.10 1.60 0.01 -0.466 12.60 10.86	SD 3 1400 3.9200 7.0600 10.0600 9.3000 9.6000 11.0400 10.0500 11.0400 10.7500 12.4400 10.5300 10.5300 10.5300	17 29 57 103 208 67 105 389 94 67 208 67 208 208 82 21 24 25 51 431 52 70 25 51 447	-1.29 -3.75 -4.30 -2.81 -2.81 -2.81 -4.70 -2.90 -5.80 -5.80 -5.80 -5.80 -1.70 -0.01 -12.10 -12.10 -14.14	SD 3 1000 7 1600 9 8800 10 3500 10 8000 11 13 3000 10 8000 11 3 3000 10 8000 10 80000 10 8000 10 8000 10 8000 10 8000 10 8000 10 8000 10 80		-1 22 -0.77 -0.74 -0.75 -0.77 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.77 -0.44 -0.77 -0.44 -0.77 -0.44 -0.77 -0.44 -0.77 -0.44 -0.77 -0.45 -0.77 -0.45 -0.77 -0.45 -0.77 -0.45 -0.77 -0.44 -0.72 -0.22	) [-1.9 3 [-1.3 9 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 1 [-0.1 3 [-0.4 3 [-0.4 3 [-0.2 3 [	2 -0.4 1 -0.2 8 -0.1 0; -0.3 1; 0.1 2; 0.4 2; -0.4 3; -0.0 8 -0.1 9; -0.0 8 -0.1 9; -0.0 8 -0.1 9; -0.0 8 -0.1 9; -0.0 8 -0.1 0; -0.0 0; -0.0 0	0)         5.5.7           0)         5.7           50)         16.3           22)         5.8           23)         5.8           24)         5.8           25)         5.8           26)         5.8           31         5.4           31         5.4           31         5.4           31         5.4           41         5.7           322)         33.1
Tothnabb-support           Mode spil           Antes Charles St. et al. 2023           Antes Charles St. et al. 2023           Antes Charles St. et al. 2023           Antes Charles St. et al. 2021           Bondem Hirths model           Marker Die del 2018           Bonden K. et al. 2021           Bonden K. et al. 2020	Total 18 31 48 87 349, p = 142 60 107 315 107 317 21 21 25 500 107 317 25 25 107 317 25 25 107 107 25 107 107 107 107 107 107 107 107	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90 -5.10 10.00 10.90 -5.10 11.60 0.01 -0.46 12.60 -0.48 -0.88 -0.48 -0.88 -0.48 -0.88 -0.48 -0.88 -0.48 -0.88 -0.48 -0.88 -0.48 -0.48 -0.88 -0.48	SD 3 1400 3 2200 7 .0600 9 3000 9 .6000 11.0400 10 0500 11.0400 10 0500 12 4400 12 4400 12 4400 12 59100 10 6500 10 6500 1	17 29 57 103 208 67 105 380 94 67 82 21 4 92 4 94 94 51 52 70 25 147 49	Hean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 -5.80 -5.80 -5.790 -5.790 -4.30 -1.70 -0.01 -1.210 -1.212 -0.01 -1.212 -0.01 -1.212 -0.01 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -0.012 -1.212 -0.012	\$D 3 1000 5.5500 7.1600 9.8800 10.3500 10.3500 10.3500 10.3500 10.2500 10.2500 10.3500 10.2500 10.		-1 22 -0.73 -0.44 -0.74 -0.74 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.72 -0.22	) [-1.9 3 [-1.3 9 [-0.8 9 [-0.8 9 [-0.7 2 [-0.8 9 [-0.7 2 [-0.8 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.5 1 [-0.5 9 [-0.5] 9 [-0.5 9 [-0.5] 9 [-0.5 9 [-0.5] 9 [-0.5 9 [-0.5] 9 [	2, -0.4 1, 0.2 8, -0.1 0; -0.3 1; 0.1 2, -0.1 0; -0.3 8, 0.1 9, -0.4 5, -0.1 8, 0.6 5, -0.1 8, 0.6 4; -0.0 3, 0.3 7, 0.2 0, 0.8 2; 0.2 8, 0.4 4; -0.0 1, 0.1 1, 0.1 1, 0.1 1, 0.1 2, -0.1 1, 0.1 2, -0.1 3, 0.0 3, 0.0 2, 0.0 8, 0.0 4, -0.0 3, 0.0 2, 0.0 8, 0.0 4, -0.0 3, 0.0 2, 0.0 8, 0.0 1, 0.0	7] 51 6] 55 6] 16.3 2] 58 6] 17.3 7] 58 6] 17.3 7] 58 6] 17.3 7] 58 6] 17.3 7] 58 7] 58
To the set of the set	Total 18 31 48 97 73 49 97 149 142 26 107 315 107 315 107 107 315 107 107 21 22 23 21 24 91 37 90 90 91 97 90 97 90 97 90 97 90 97 90 97 90 97 90 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 90 97 90 90 97 90 90 97 90 90 90 90 90 90 90 90 90 90	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90 -0.510 -5.10 10.00 10.00 -0.510 10.00 -0.510 -0.20 -0.466 -0.22 -0.466 -0.26	SD 3 1400 3.9200 7.0600 10.0600 9.3000 9.6000 11.0400 10.0500 11.0400 10.7500 12.4400 10.5300 10.5300 10.5300	17 29 57 103 208 67 105 389 94 67 208 67 208 208 82 21 24 25 51 431 52 70 25 51 447	Hean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 -5.80 -5.80 -5.790 -5.790 -4.30 -1.70 -0.01 -1.210 -1.212 -0.01 -1.212 -0.01 -1.212 -0.01 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -0.012 -1.212 -0.012	SD 3 1000 7 1600 9 8800 10 3500 10 8000 11 13 3000 10 8000 11 3 3000 10 8000 10 80000 10 8000 10 8000 10 8000 10 8000 10 8000 10 8000 10 80		-1 22 -0.73 -0.64 -0.67 -0.75 -0.74 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.75 -0.77 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.77 -0.77 -0.77 -0.44	) [-1.9 3 [-1.3 9 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 1 [-0.1 3 [-0.4 3 [-0.4 3 [-0.2 3 [	2, -0.4 1, 0.2 3, -0.1 1, 0.1 2, -0.4 3, -0.1 3, 0.3 3, 0.3 3, 0.3 3, 0.3 2, 0.2 6, 0.4 1, 3, 9 1, 0.1 1, 0.1 1	7] 51 6] 55 6] 16.3 7] 58 16.3 7] 58 6] 16.3 7] 58 6] 16.3 7] 58 6] 5
To the half h-support of the second	Total 18 31 48 97 73 49 97 149 142 26 107 315 107 315 107 107 315 107 107 21 22 23 21 24 91 37 90 90 91 97 90 97 90 97 90 97 90 97 90 97 90 97 90 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 97 90 90 97 90 90 97 90 90 97 90 90 90 90 90 90 90 90 90 90	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -3.70 10.00 10.90 -0.510 -5.10 10.00 10.00 -0.510 10.00 -0.510 -0.20 -0.466 -0.22 -0.466 -0.26	SD 3 1400 3 2200 7 .0600 9 3000 9 .6000 11.0400 10 0500 11.0400 10 0500 12 4400 12 4400 12 4400 12 59100 10 6500 10 6500 1	17 29 57 103 208 67 105 389 94 67 82 21 24 94 431 52 70 52 51 147 94 932	Hean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 -5.80 -5.80 -5.790 -5.790 -4.30 -1.70 -0.01 -1.210 -1.212 -0.01 -1.212 -0.01 -1.212 -0.01 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -0.012 -1.212 -0.012	\$D 3 1000 5.5500 7.1600 9.8800 10.3500 10.3500 10.3500 10.3500 10.2500 10.2500 10.3500 10.2500 10.		-1 22 -0.73 -0.64 -0.67 -0.75 -0.74 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.75 -0.77 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.44 -0.77 -0.77 -0.77 -0.44	) [-1.9 3 [-1.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.4 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.3 9 [-0.4 9 [-0.4] 9 [-0.4 9 [-0.4] 9 [-0.4 9 [-0.4] 9 [-0.4 9 [-0.4] 9 [-0.4] 9 [-0.4 9 [-0.4] 9 [	2, -0.4 1, 0.2 3, -0.1 1, 0.1 2, -0.4 3, -0.1 3, 0.3 3, 0.3 3, 0.3 3, 0.3 2, 0.2 6, 0.4 1, 3, 9 1, 0.1 1, 0.1 1	7] 51 6] 55 6] 16.3 7] 58 16.3 7] 58 6] 16.3 7] 58 6] 16.3 7] 58 6] 5
To the half h-support of the second	Total 18 18 31 48 97 97 142 66 107 315 620 p < 620 72 25 6 102 60 60 60 60 60 60 60 60 60 60 60 60 60	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -9.30 0.01 -3.70 10.90 -0.510 -0.510 -0.510 10.90 0.01 -0.46 12.60 -0.46 0.22 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20	SD 3 1400 3 9200 7 0600 9 3000 9 3000 9 3000 9 3000 9 3000 11 0400 10 7500 13 9700 13 9700 13 9700 13 9700 10 6600 10 7500 10 75000 10 7500 10 7500 10 7500 10 7500 10 75000 10 75	17 29 57 103 208 67 105 389 94 67 72 24 24 431 52 51 431 52 700 55 147 94 51 51 24 431	Hean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 -5.80 -5.80 -5.790 -5.790 -4.30 -1.70 -0.01 -1.210 -1.212 -0.01 -1.212 -0.01 -1.212 -0.01 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -0.012 -1.212 -0.012	\$D 3 1000 5.5500 7.1600 9.8800 10.3500 10.3500 10.3500 10.3500 10.2500 10.2500 10.3500 10.2500 10.		-122 -073 -044 -073 -064 -044 -044 -044 -044 -044 -044 -044	) [-1.9 3 [-1.3 3 [-1.3 3 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 3 [-0.3 3 [-0.3 3 [-0.3 3 [-0.2 3 [-0.2] 3 [-0.2 3 [-0.2 3 [-0.2] 3 [	2, -0.4 1, -0.2 3, -0.1 1, 0.1 2, -0.4 1, 0.1 2, -0.4 3, -0.1 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 1, -0.9 5, 0.1 5, 0.1 5, 0.1 6, 0.1 5, 0.1 6,	7] 51 6] 55 6] 16.3 7] 58 16.3 7] 58 6] 16.3 7] 58 6] 16.3 7] 58 6] 5
To the half h-support of the second	Total 18 18 31 48 97 97 142 66 107 315 620 p < 620 72 25 6 102 60 60 60 60 60 60 60 60 60 60 60 60 60	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -9.30 0.01 -3.70 10.90 -0.510 -0.510 -0.510 10.90 0.01 -0.46 12.60 -0.46 0.22 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20	SD 3 1400 3 9200 7 0600 9 3000 9 3000 9 3000 9 3000 9 3000 11 0400 10 7500 13 9700 13 9700 13 9700 13 9700 10 6600 10 7500 10 75000 10 7500 10 7500 10 7500 10 7500 10 75000 10 75	17 29 57 103 208 67 105 389 94 67 72 24 24 431 52 51 431 52 700 55 147 94 51 51 24 431	Hean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 -5.80 -5.80 -5.790 -5.790 -4.30 -1.70 -0.01 -1.210 -1.212 -0.01 -1.212 -0.01 -1.212 -0.01 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -0.012 -1.212 -0.012	\$D 3 1000 5.5500 7.1600 9.8800 10.3500 10.3500 10.3500 10.3500 10.2500 10.2500 10.3500 10.2500 10.		-122 -024 -044 -044 -077 -044 -044 -044 -044 -04	) [-1.9 3 [-1.3 3 [-1.3 3 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 3 [-0.3 3 [-0.3 3 [-0.3 3 [-0.2 3 [	2, -0.4 1, -0.2 3, -0.1 1, 0.1 2, -0.4 1, 0.1 2, -0.4 3, -0.1 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 1, -0.9 5, 0.1 5, 0.1 5, 0.1 6, 0.1 5, 0.1 6,	7] 5 1 5 16.3 2] 58,7 5,8 4] 17.3 2] 58,7 5,8 4] 17.3 5,8 4] 17.3 5,8 5,8 5,8 5,8 5,8 5,8 5,8 5,8
To the half h-support of the second	Total 18 18 31 48 97 97 142 66 107 315 620 p < 620 72 25 6 102 60 60 60 60 60 60 60 60 60 60 60 60 60	Mean -5.11 -7.32 -7.80 0.22 -3.75 14.40 -9.30 0.01 -9.30 0.01 -3.70 10.90 -0.510 -0.510 -0.510 10.90 0.01 -0.46 12.60 -0.46 0.22 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20 -3.68 -0.20	SD 3 1400 3 9200 7 0600 9 3000 9 3000 9 3000 9 3000 9 3000 11 0400 10 7500 13 9700 13 9700 13 9700 13 9700 10 6600 10 7500 10 75000 10 7500 10 7500 10 7500 10 7500 10 75000 10 75	17 29 57 103 208 67 105 389 94 67 72 24 24 431 52 51 431 52 700 55 147 94 51 51 24 431	Hean -1.29 -3.75 -4.30 -2.81 -6.80 -4.70 -5.80 -5.80 -5.790 -5.790 -4.30 -1.70 -0.01 -1.210 -1.212 -0.01 -1.212 -0.01 -1.212 -0.01 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -1.212 -0.012 -0.012 -1.212 -0.012	\$D 3 1000 5,5500 7,1600 9,8800 10,3500 10,3500 10,3500 10,3500 10,2500 10,2500 10,2500 10,2500 10,3500 10,		-122 -024 -044 -044 -077 -044 -044 -044 -044 -04	) [-1.9 3 [-1.3 3 [-1.3 3 [-0.3 7 [-1.1 5 [-0.7 2 [-0.8 2 [-0.8 2 [-0.8 2 [-0.8 3 [-0.3 3 [-0.3 3 [-0.3 3 [-0.2 3 [	2, -0.4 1, -0.2 3, -0.1 1, 0.1 2, -0.4 1, 0.1 2, -0.4 3, -0.1 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 3, 0.3 7, 0.2 0, 0.8 4, -0.0 1, -0.9 5, 0.1 5, 0.1 5, 0.1 6, 0.1 5, 0.1 6,	7] 5.6 0] 5.6 0] 5.7 0] 5.7 0] 5.7 0] 5.7 16] 16.3 2] 5.8 2] 5.8 2] 5.8 3] 5.8 4] 17.3 5.8 4] 17.3 5.8 4] 5.7 5.8 4] 5.8 5.8 5.8 5.8 5.8 5.8 5.8 5.8

### Figure 4

See image above for figure legend.

Figure 5: Subgroup analysis of pain and physical function based on the control group



### Figure 5

See image above for figure legend.

### **Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

SUPPLEMENTARYMATERIAL.docx